Method for making hormone heterodimers

Abstract

The present invention relates to a method for preparing heterodimeric analogs of cysteine knot proteins. More specifically, the invention relates to a method for forming a subunit combination of a cysteine knot protein having an α-subunit and a β-subunit to prepare a heterodimeric protein analog which comprises the steps of (a) attaching a dimerization domain to the amino termini of both an α-subunit and β-subunit of a cysteine knot protein; and (b) dimerizing the α-subunit and β-subunit to form a heterodimeric protein analog. In another embodiment, the invention relates to a method for forming a subunit combination of a cysteine knot protein having an α-subunit and a β-subunit to prepare a heterodimeric protein analog which comprises the steps of (a) attaching a dimerization domain to the amino terminus of an α-subunit and the carboxy terminus of a β-subunit of a cysteine knot protein; and (b) dimerizing the α-subunit and β-subunit to form a heterodimeric protein analog.

Description

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to a method for preparing heterodimeric analogs of cysteine knot proteins. More specifically, the invention relates to a method for forming a subunit combination of a cysteine knot protein having an α-subunit and a β-subunit to prepare a heterodimeric protein analog which comprises the steps of (a) attaching a dimerization domain to the amino termini of both an α-subunit and a β-subunit of a cysteine knot protein; and (b) dimerizing the α-subunit and β-subunit to form a heterodimeric protein analog. In another embodiment, the invention relates to a method for forming a subunit combination of a cysteine knot protein having an α-subunit and a β-subunit to prepare a heterodimeric protein analog which comprises the steps of (a) attaching a dimerization domain to the amino terminus of an α-subunit and the carboxy terminus of a β-subunit of a cysteine knot protein; and (b) dimerizing the α-subunit and β-subunit to form a heterodimeric protein analog.

2. Description of the Background

The disclosures referred to herein to illustrate the background of the invention and to provide additional detail with respect to its practice are incorporated herein by reference and, for convenience, are numerically referenced in the following text and respectively grouped in the appended bibliography.

The Glycoprotein Hormones and Their Biological Actions

The glycoprotein hormone family (1-3) consists of three α, β heterodimeric glycoproteins found in the anterior pituitary gland where they are made and includes luteinizing hormone (LH), follicle stimulating hormone (FSH), and thyroid stimulating hormone (TSH). These hormones are found in most, if not all vertebrates. In some species, a glycoprotein hormone structurally similar to LH is found in the placenta wherein it is synthesized. The human placental hormone is known as human chorionic gonadotropin (hCG). In primates, significant quantities of all the hormones are also found as excretion products in urine. Urine from pregnant women serves as a convenient source of hCG. After menopause, when the secretion of LH and FSH from the anterior pituitary is greatly increased, significant quantities of LH and FSH are found in the urine and are termed human menopausal gonadotropins (hMG). Urine from menopausal women serves as an important source of LH and FSH activities. Urinary hormones (hCG, hMG, hFSH) and recombinant hormones have important clinical and commercial uses.

Gonadotropins such as CG, LH, and FSH play a major role in the reproductive process (4) while the structurally related hormone, TSH, is important for thyroid function. In women, FSH plays a crucial role in the development of follicles that can be ovulated, primarily through its influence on granulosa cells. LH synergizes with FSH and is normally essential for processes of ovulation, luteinization, and luteal function. Nonetheless, high LH levels can reduce fertility and are thought partly responsible for the loss of fertility associated with polycystic ovarian disease. hCG is important for maintenance of pregnancy and its early neutralization leads to infertility. In males LH is required for puberty and, in its absence, there is a failure to acquire the sexual attributes and fertility of an adult. The biological and clinical activities of these hormones are reviewed extensively in several textbooks including those by Yen and Jaffe (4), Adashi, Rock, and Rosenwaks (5), and DeGroot (6).

Both hCG and LH bind to luteinizing hormone receptors (LHR). In the testis, LHR are found primarily in the Leydig cells. In the ovary, LHR are found primarily in thecal cells, FSH-stimulated granulosa cells, and luteal cells. The major role of LH is to stimulate the formation of steroid hormones including the androgens testosterone and androstenedione (Leydig and thecal cells) and progesterone (FSH-stimulated granulosa, thecal, and luteal cells). LH also causes ovulation of mature follicles. While hCG is normally produced only by the placenta during pregnancy, due to its high affinity for LH receptors, the ease with which it can be purified from urine, and its long biological half-life, hCG has been widely used as a substitute for LH. Important clinical uses for hCG include stimulation of fertility in males and induction of ovulation in females.

FSH binds to FSH receptors (FSHR) located primarily in the Sertoli cells of the testis and the granulosa cells of the ovaries. The primary roles of FSH are to stimulate the conversion of androgens to estrogens, to promote the synthesis of inhibin and activin, to promote the development of Sertoli and granulosa cells, and to stimulate gamete maturation. The effect of FSH on granulosa cells leads to follicular maturation, a process during which the oocyte is prepared for ovulation and in which the granulosa cells acquire the ability to respond to LH. Follicle maturation is essential for the ability of LH to induce ovulation.

The differences in the effects of FSH and LH and the complex endocrine interactions between the two hormones cause them to have synergistic effects. For example, normal estrogen production is due to the effect of LH on androgen formation and the influence of FSH on the conversion of androgens to estradiol. Estrogens can inhibit the secretion of FSH and potentiate the secretion of LH. The ability of androgens to be converted to estrogens in non-ovarian tissues can disrupt this complex feedback interaction between steroidogenesis and the secretion of FSH and LH. For this reason, the ratio of LH/FSH activity as well as the absolute hormone levels in blood are important for reproductive functions such as ovulation of the proper number of oocytes during the menstrual and estrus cycles. Other hormones including activin and inhibin can exert an influence on this process, primarily through their influence on FSH secretion from the pituitary gland and their influence on the ovarian response to FSH.

TSH is produced in the anterior pituitary gland and its major function is to regulate the activity of the thyroid gland, causing it to synthesize and release thyroxin. Circulating levels of TSH and thyroxin are usually regulated by a negative feedback mechanism. Increases in TSH secretion usually lead to increased thyroxin synthesis and secretion by the thyroid. As thyroxin levels increase, the secretion of TSH is decreased. In this way there is a balance between the level of TSH and thyroid hormone. High levels of TSH can also stimulate the thyroid gland to remove iodine from circulation. Clinically, TSH can be used to promote the uptake of radioactive iodine and death of the thyroid cells. This form of thyroidectomy has been used to remove hyperactive thyroid tissues.

Uses of Glycoprotein Hormones and the Desirability of Novel Hormone Analogs

Hormones with FSH and LH activities are routinely used in the treatment of human infertility, a problem experienced by approximately 10-15% of all couples (7,8). A major cause of female infertility is polycystic ovarian disease or syndrome, a condition in which endogenous LH levels often appear to be elevated. In principle, infertility caused by inappropriately high LH activity could be suppressed by administration of an inhibitory hormone analog that competed with LH for binding to LHR. It has been known for many years (9,10) that it is possible to prepare analogs of hCG that act as LH antagonists by removing all or part of the oligosaccharides from the hormone. While it is possible to remove most of the oligosaccharides using endonucleases or exonucleases, in practice, it is not practical to remove all of them without denaturing the hormones. The remaining sugars can serve as substrates for enzymes and other factors that can hasten removal of the proteins from circulation (11-13). One potential means of avoiding this problem is to prepare analogs that have been genetically deglycosylated (i.e., by replacing or deleting amino acids in the signals needed for N-linked glycosylation). These signals have the amino acid sequence Asn-Xaa-Ser/Thr where Asn is asparagine, Xaa is any amino acid except proline, and Ser/Thr are serine or threonine. To disrupt glycosylation, Asn can be changed to any other amino acid, Xaa can be changed to proline and/or Ser or Thr can be changed to any other amino acids.

Using genetic deglycosylation, it has been shown that the oligosaccharide from the hCG α-subunit at Asn52 has the greatest influence on signal transduction (10). Removal of this oligosaccharide leads to a substantial loss in hormone efficacy and enables the preparation of a partial agonist that can partially inhibit the response to hCG. However, because the other hormone oligosaccharides also influence signal transduction, preparation of the most potent antagonists requires that other N-linked amino acids, particularly those on the α-subunit, be removed from the hormone (10). Unfortunately, removal of the α-subunit oligosaccharide at Asn52 reduces the abilities of the α- and β-subunits to combine (10,14-16). While small amounts of heterodimer do form and can be studied in a laboratory setting (10), preparation of larger quantities needed for potential therapeutic uses is impractical. Methods for improving the production of deglycosylated glycoprotein hormone analogs are desirable and, as described later, one such method involves addition of dimerization sequences to the hormone subunits.

Hormone analogs that have prolonged half-lives or universal activities also have potential important uses. It is well known that the half-lives of the subunits is significantly shorter than that of the heterodimers [reviewed in Moyle and Campbell (2)]. Because dimerization domains can potentiate formation of heterodimers, they can also reduce the rate of hormone dissociation and influence circulation time. Hormone analogs that serve as immunogens are also potentially important. Dimerization domains can contain high immunogenic amino acid sequences and therefore increase the immunogenicity of the analogs.

Structures of the Glycoprotein Hormones

The structures of the glycoprotein hormones have been studied for many years and the relative roles of the hormone subunits in receptor binding specificity are well-known (1). Glycoprotein hormones share a common α-subunit and differ in their hormone-specific β-subunits. The latter determine the biological and immunological properties of each hormone. Substitution of the α-subunit of any one hormone for that of another does not change the receptor binding properties of the new hormone. Substitution of the β-subunit is accompanied by a change in receptor binding specificity. Thus, when FSH β-subunit is substituted for the LH β-subunit, the recombined hormone acquires the properties of FSH and loses properties characteristic of LH. The sequences of many hormone subunits were determined several years ago and have been confirmed by their genomic and cDNA sequences (17-21).

The crystal structure of hCG determined in two laboratories (22,23) showed that each subunit had the overall topology characteristic of cysteine knot proteins (24). Each subunit is divided into three large loops by disulfide bonds that create the cysteine knot. Since the relative positions of the cysteines in all the glycoprotein hormones are very similar, it is nearly certain that the β-subunits of LH, FSH, and TSH will also have a cysteine knot architecture. The β-subunit differs from the α-subunit in one important aspect, namely the presence of an additional sequence of approximately twenty amino acids that is attached to the C-terminal cysteine of the cysteine knot. In the β-subunits of hLH, hCG, hFSH, and hTSH, the seatbelt corresponds to amino acid residues Gly91-Cys110, Ala91-Cys110, Gly85-Cys104, and Gly86-Cys105, respectively. This sequence was termed the seatbelt (22) because it is wrapped around the α-subunit and forms a disulfide bond with a cysteine in β-subunit loop 1 to stabilize the heterodimer. As reviewed by Ruddon and colleagues, the cysteine knot that latches the seatbelt appears to be one of the final steps in β-subunit folding and appears to occur after the two subunits have combined (25).

Several attempts have been made to identify portions of the α- and β-subunits of the hormones that are responsible for their unique biological properties. Earlier studies were based on chemical modifications of the hormones (1). Modifications were described that reduced the biological activities of the hormones. Due to the complexity of the hormones, this approach was usually unable to identify single amino acid residues that were involved in receptor binding or binding specificity. In an attempt to simplify the problem of identifying residues involved in receptor binding, some investigators prepared synthetic peptides corresponding to partial sequences of the α- and β-subunits and monitored their abilities to inhibit binding of 125 I-hCG and 125 I-hFSH to LH and FSH receptors. Synthetic peptides corresponding to amino acid residues of hCG β-subunit 38-57 or hFSH β-subunit 31-52 appear to have higher abilities than most other peptides in these assays (26-29). However, they have extremely low affinities for the receptors, an observation that precludes their practical use.

A breakthrough in the ability to make and characterize glycoprotein hormone analogs came in 1985 when genetically engineered mammalian cells were first shown to express biologically active hCG heterodimers (30). Since that time several laboratories have used mammalian cells to express glycoprotein hormone analogs that are capable of binding to receptors and inducing or inhibiting signal transduction (14,31-37). These analogs appear to be glycosylated similarly to the naturally occurring hormones. In these procedures one introduces a “gene” that encodes the desired amino acid sequences into mammalian cells downstream of a promoter. Construction of these genes is a standard recombinant DNA procedure. By changing, adding and/or deleting codons in the hormone α- or β-subunit cDNAs or genomic DNA fragments using standard procedures, it is possible to build gene constructs that encode the desired analogs (38,39). When these constructs are transfected into mammalian cells by calcium phosphate precipitation, electroporation, or other standard protocols (38-40), they direct the synthesis of the hormone analogs and their secretion into the culture media. These media can be assayed for the presence of immunological or biological activity (31,32,41). Unfortunately, not all such constructs yield practical amounts of heterodimers. This is especially evident with hormones that lack one or more glycosylation signals.

Using mammalian cell expression systems to make hormone analogs, Campbell, et al. (31) showed that it was possible to switch the receptor binding activity of hCG. They engineered an analog that was chemically and immunologically more similar to hCG than hFSH, but that bound to FSH receptors much better than hCG and had only slightly higher affinity for LH receptors than FSH. Subsequent reports (33) showed that it was possible to prepare analogs of hCG that had a high affinity for both LH and FSH receptors. This was accomplished by replacing hCG seatbelt residues 101-109 with their hFSH β-subunit counterparts (i.e., hFSH β-subunit residues 95-103). These hCG analogs (31,33) elicit signal transduction at either LH and/or FSH receptors. This demonstrated that the seatbelt of the β-subunit had a major influence on receptor binding specificity. It is anticipated that removing the oligosaccharides from analogs in which the specificity is modified by substitutions in the seatbelt will reduce their efficacy and cause them to become partial agonists and/or antagonists. Their ability to bind to receptors requires that the β-subunits of these analogs combine with the α-subunit to form heterodimers. The method described here will be useful for expressing these analogs as heterodimers and represents a significant advance in heterodimer preparation.

Slaughter et al. (42) showed that an interaction between the N-terminal portion of hCG β-subunit and the seatbelt had a substantial influence on subunit combination. Removal of the hCG β-subunit N-terminus led to loss in its ability to combine with the α-subunit to form a heterodimer. This could be restored in part by changing the seatbelt residues of the β-subunit to those found in the β-subunit of hFSH. This suggested that interactions between different parts of the hormone subunits had significant roles in subunit combination. It also suggested that subunit combination was complex and that any modification of this region of the hCG β-subunit might be expected to interfere with subunit combination. Indeed, work by Keutmann and colleagues (43) showed that synthetic peptides similar in structure to the N-Terminal region of the hCG β-subunit inhibited subunit combination and that this portion of hCG was likely to be near the α-subunit.

Sugahara et al. (44) showed that a fusion protein between the α- and β-subunits would lead to a protein that had many of the same properties as the heterodimeric parental molecule, including the ability to bind to receptors. Nonetheless, these analogs have all the amino acids of the protein connected together in a single-chain and therefore differ substantially from proteins that have two subunits. Unlike single chain proteins that are folded differently from the native hormones, hormone analogs that have two separate subunits similar to those found naturally would be expected to have receptor binding and immunological properties that are more similar to those of the parental molecules.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 illustrates the coding sequence of the hCG β-subunit cDNA between the XhoI and BamHI sites except that the codons for amino acids 2-8 have been deleted.

FIG. 2 illustrates the coding sequence of a vector that encodes the hCG β-subunit signal sequence upstream (5′) of bases that encode serine, cysteine, two glycines, and portions of the Fos dimerization domain (one letter code).

FIG. 3 illustrates the coding sequence of a vector that encodes the hCG β-subunit signal sequence upstream (5′) of bases that encode serine, cysteine, two glycines, and portions of the Jun dimerization domain (one letter code).

FIG. 4 illustrates the sequences of oligonucleotides used in this work including primers used to create a cassette that permitted insertion of the Fos and Jun dimerization domain amino acid coding sequences into the construct illustrated in FIG. 1 .

FIG. 5 shows the coding sequence of the entire Fos-hCG-α-subunit construct.

FIG. 6 shows the coding sequence of the entire Jun-hCGβ′-subunit construct.

FIG. 7 shows that the heterodimer containing the Fos-Jun amino acid sequences at its N-termini can stimulate signal transduction in a similar fashion as hCG.

FIG. 8 shows that the heterodimer containing the Fos-Jun amino acid sequences at its N-termini can inhibit the binding of radioiodinated hCG to CHO cells expressing rat LH receptors in a similar fashion as hCG.

FIG. 9 illustrates the sequence of an α-subunit construct that is lacking the glycosylation signal normally found at Asn52 of the mature human α-subunit.

FIG. 10 illustrates the sequence of the Fos-α-subunit construct that is lacking the glycosylation signal corresponding to human α-subunit residue 52 caused by substitution of an aspartic acid residue for the asparagine normally found at this residue of the human α-subunit.

FIG. 11 illustrates the sequence of the Fos-α-subunit construct in which the cysteine normally found at position 7 of the human α-subunit has been replaced by an alanine.

FIG. 12 illustrates the sequence of the Jun-hCGβ′-subunit in which the tyrosine normally found in the hCG β-subunit at residue 37 has been replaced by a cysteine.

FIG. 13 illustrates the Jun-hCGβ′-Y37C-C26A construct.

FIG. 14 illustrates the Jun-hCGβ′-Y37C-C26A-δ92 construct.

FIG. 15 illustrates the abilities of hFSH, hCG, Fos-Jun-hCG-SS/δseatbelt, and Fos-Jun-hCG-SS to stimulate signal transduction in CHO cells expressing human FSH receptors.

FIG. 16 illustrates the abilities of bovine TSH, hCG, Fos-Jun-hCG-SeS/δseatbelt, and Fos-Jun-hCG-SS to stimulate signal transduction in CHO cells expressing human FSH receptors.

FIG. 17 illustrates the sequences of constructs of Fos-hCG α-subunit containing a furin cleavage site and the sequences of Jun-hCG β-subunit, Jun-hLH β-subunit, Jun-hFSH β-subunit, Jun-hTSH β-subunit, Jun-hCG/hFSH β-subunit chimera, and Jun-hCG/hTSH β-subunit chimera containing a furin cleavage site.

FIG. 18 illustrates the sequences of constructs containing immunoglobulin dimerization domains at their N-termini.

FIG. 19 illustrates the sequences of constructs containing immunoglobulin dimerization domains at their N-termini.

FIG. 20 illustrates the amino acid sequences of β-subunit constructs containing the dimerization domain from Jun at the carboxyterminus of their dimerization domains.

SUMMARY OF THE INVENTION

The present invention pertains to a method for forming a subunit combination of a cysteine knot protein having an α-subunit and a β-subunit to prepare a heterodimeric protein analog which comprises the steps of:

(a) attaching a dimerization domain to the amino termini of both an α-subunit and a β-subunit of a cysteine knot protein; and

(b) dimerizing the α-subunit and β-subunit to form a heterodimeric protein analog.

In a preferred embodiment, a Fos dimerization sequence domain is attached to the amino-terminus of the β-subunit and a Jun dimerization sequence domain is attached to the amino-terminus of the α-subunit. In another preferred embodiment, a Fos dimerization sequence domain is attached to the amino-terminus of the α-subunit and a Jun dimerization sequence domain is attached to the amino-terminus of the β-subunit. A glycine or serine residue may be inserted between the Fos or Jun dimerization sequence domain and a furin cleavage site to facilitate cleavage of the dimerization sequence domain from the heterodimer. The dimerization domain may also be a heavy or light chain of an immunoglobulin. The heterodimeric protein analog may be a glycoprotein hormone heterodimer selected from the group consisting of hCG, hLH, hFSH, hTSH, TGFβ, PDGF, NGF, Veg1, bone morphogenic proteins, activin, inhibin, and analogs thereof. The heterodimeric protein analog may also be selected from the group consisting of hCG/hFSH chimeras, hCG/hTSH chimeras, deglycosylated hormones, truncated glycoprotein hormones, mutant glycoprotein hormones, and glycoprotein hormones containing an hCG carboxyl terminus. Protease cleavage sites may be incorporated between additional N-terminal sequences and the α-subunit and the β-subunit of the cysteine knot protein to remove the dimerization domains from the heterodimeric protein analog. The cysteine knot protein may be a glycoprotein hormone heterodimer having the oligosaccharide genetically removed from the α-subunit at Asn52. The cysteine knot protein may also be a glycoprotein hormone heterodimer lacking a seatbelt.

In another embodiment, the present invention pertains to a method for forming a subunit combination of a cysteine knot protein having an α-subunit and a β-subunit to prepare a heterodimeric protein analog which comprises the steps of:

(a) attaching a dimerization domain to the amino terminus of an α-subunit and the carboxy terminus of a β-subunit of a cysteine knot protein; and

(b) dimerizing the α-subunit and β-subunit to form a heterodimeric protein analog.

In a preferred embodiment, a Fos dimerization sequence domain is attached to the carboxy-terminus of the β-subunit and a Jun dimerization sequence domain is attached to the amino-terminus of the α-subunit. In another preferred embodiment, a Fos dimerization sequence domain is attached to the amino-terminus of the α-subunit and a Jun dimerization sequence domain is attached to the carboxy terminus of the β-subunit. A protease cleavage site may be inserted between the dimerization sequence domain and the α-subunit and a protease cleavage site may be inserted between the dimerization sequence domain and the β-subunit. Preferably, the protease cleavage site is furin. The dimerization domain may be a heavy or light chain of an immunoglobulin. The heterodimeric protein analog may be selected from the group consisting of hCG/hFSH chimeras, hCG/hTSH chimeras, deglycosylated hormones, truncated glycoprotein hormones, mutant glycoprotein hormones, and glycoprotein hormones containing an hCG carboxyl terminus. The cysteine knot protein may be a glycoprotein hormone heterodimer having the oligosaccharide genetically removed from the α-subunit at Asn52.

DETAILED DESCRIPTION OF THE INVENTION

Human chorionic gonadotropin (hCG), luteinizing hormone (LH), follicle stimulating hormone (FSH), and thyroid stimulating hormone (TSH) are members of the heterodimeric glycoprotein hormone family. LH and hCG bind to LH receptors (LHR), FSH binds to FSH receptors (FSHR), and TSH binds to TSH receptors (TSHR). Interactions of LH and FSH with gonadal LHR and FSHR are essential for fertility. Interactions of TSH with TSHR are essential for proper functioning of the thyroid gland. All four hormones are heterodimers containing an α-subunit produced from the same gene and a hormone-specific β-subunit. The crystal structure of hCG shows that both subunits are members of the cysteine knot family of proteins. Because the endocrine activities of the heterodimers exceed those of the isolated subunits, it is usually desirable to prepare heterodimers in which the α- and β-subunits are combined similarly to the native hormones. Formation of non-native or mutant heterodimers is often impeded by changes to one or both subunits needed to elicit desirable properties. The present method promotes subunit combination of the cysteine knot family of proteins and thereby improves the synthesis of heterodimeric hormone analogs. This method involves attaching dimerization domains to the amino termini of both hormone subunits, a process that facilitates combination of the remainder of the proteins into active heterodimers. By incorporating appropriate protease cleavage sites between the additional N-terminal sequences and the α- and β-subunits, it is also possible to remove the dimerization domains from the hormone dimers to create hormone analogs that are similar in structure to the native molecules.

By employing the method of the present invention, it is possible to increase the efficiency of subunit combination for subunits that would otherwise not combine or that would combine very poorly by adding sequences dimerization domains to the N-terminus of each subunit. This method can also be applied to the preparation of glycoprotein hormone heterodimers in which the oligosaccharide has been genetically removed from the α-subunit at Asn52. This method can also be used to produce heterodimers lacking the seatbelt. The method outlined in this invention should be useful for facilitating the dimerization of any cysteine knot proteins including but not limited to TGFβ, PDGF, NGF, Veg1, bone morphogenic proteins, activin, inhibin and their analogs. The present invention also teaches that the N-terminal portions of the glycoprotein hormones can be modified without disrupting the activity of the protein.

The dimerization domain strategy can be used to prepare any heterodimeric analog of the glycoprotein hormones, glycoprotein hormone including hCG/hFSH and hCG/hTSH chimeras (31,33,48,52) and/or deglycosylated hormones including those missing oligosaccharides at one or more positions on the α- or β-subunits (10), truncated glycoprotein hormone subunits, glycoprotein hormone subunits containing the hCG carboxyl terminus (52), glycoprotein hormones from different vertebrates, glycoprotein hormones in which the subunits are derived from different species, and heterodimers of other members of the cysteine knot family. Most members of the cysteine knot family with the exception of the glycoprotein hormones contain their own dimerization domains that are included in the “pro” portion of the prohormone. Dimerization domains from these other cysteine knot proteins can be substituted for the Fos and Jun sequences described above to promote dimerization of the glycoprotein hormones. In addition, the use of Fos, Jun, or other dimerization domains will facilitate production of heterodimeric cysteine knot proteins. For example, inhibin is composed of an α- and a β-subunit. When these are expressed in the same cell there is the potential for the formation of activin, a ββ homodimer, particularly when the Fos dimerization sequence is added to the N-terminus of the β-subunit and the Jun dimerization sequence is added to the N-terminus of the α-subunit. Use of the Fos-Jun or other heterodimerization strategy outlined here is expected to reduce the formation of these homodimers and facilitate the production of heterodimers that inhibit rather than potentiate FSH secretion. It should also be noted that the furin cleavage site can be replaced with other cleavage sites. In addition, residues such as glycine and/or serine can be inserted between the Fos or Jun and the furin cleavage sites to facilitate cleavage of the dimerization domain from the remainder of the heterodimer. The heterodimers produced by addition of the dimerization domains will retain the properties of the native or mutant hormones produced without the presence of the dimerization domains. The heterodimers produced by addition of the dimerization domains will also serve as useful antigens. Thus, when the dimerization domain is retained on the protein, its antigenicity will be enhanced. When the dimerization domain is used to produce a protein containing a subunit or part of a subunit from a different species, its antigenicity will also be enhanced.

EXAMPLE 1

Preparation and Characterization of Fos-Jun hCG, an hCG Analog Containing the Dimerization Domain of Fos Attached to the N-terminus of the α-subunit and the Dimerization Domain of Jun Attached to the N-terminus of the β-subunit

The hCG β-subunit cDNA was modified to add an NheI restriction endonuclease site at the end of the leader sequence (FIG. 1 ). This enabled insertion of the dimerization domains of Fos or Jun at the C-terminal end of the hCG β-subunit signal sequence. The modification was made by manipulating the sequence of the naturally occurring hCG β-subunit cDNA starting with vectors that have been described (31,32,42). The coding sequence of the resulting vector is shown in FIG. 1 . When this coding sequence is expressed in mammalian cells, the signal sequence (i.e., amino acids MEMFQGLLLLLLLSMGGTWA, (SEQ. ID NO: 384) single amino acid code) will be removed and like the hCG β-subunit, the resulting protein should have a serine residue at its N-terminus. The codons between the NheI and BamHI restriction sites shown in FIG. 1 were replaced with bases that included the coding sequences for the portions of the Fos and Jun dimerization domains capable of forming heterodimers. This created the constructs shown in FIGS. 2 and 3 . The Fos construct was prepared by annealing oligonucleotides 1002 and 1003 ( FIG. 4 ) and filling them in with Vent Polymerase (New England Biolabs, Beverly, Mass.). Oligonucleotides 1004 and 1005 ( FIG. 4 ) were used in a polymerase chain reaction (PCR) with the filled-in product of oligonucleotides 1002 and 1003 to produce a DNA fragment approximately 175 base pairs long. This was purified by agarose gel electrophoresis, digested with NheI and BamHI and the large fragment that resulted was subcloned into the NheI-BamHI sites of the construct shown in FIG. 1 to produce the construct shown in FIG. 2 . The Jun construct ( FIG. 3 ) was prepared in a similar fashion except that oligonucleotides 1006 and 1007 ( FIG. 4 ) were used for the fill-in reaction and oligonucleotides 1008 and 1009 ( FIG. 4 ) were used for PCR.

Following DNA sequencing to make certain that the complex having the desired codons had been obtained, the construct containing the Fos codons described in FIG. 2 was digested with BsmI and BamHI. The short piece of DNA between these sites was replaced with the BsmI-BamHI digestion product of the human α-subunit cDNA to create the construct containing the codons illustrated in FIG. 5 . The final coding construct shown in FIG. 5 was then subcloned into an expression vector (pCI′) that was a modification of pCI, a vector obtained from promega, Madison, Wis. and created pCI′-Fos-α. The modification of pCI to create pCI′ consisted of moving the BamHI site from a region outside the polyadenylation signal to a position near the 3′ end of the polylinker. This was accomplished using the polymerase chain reaction and was done to facilitate cloning the coding constructs into the expression vector. It is not necessary to use this vector to observe expression in mammalian cells. Virtually any vector capable of expressing proteins in mammalian cells will suffice including that known as pSVL, commercially available from Pharmacia Co., Piscataway, N.J. pSVL can be used directly without modification since it contains a polylinker with appropriately positioned XhoI and BamHI sites to facilitate the cloning and expression of the protein.

Using a similar strategy, a DNA construct that encodes a sequence having the hCG β-subunit leader, a segment related to the Jun oncoprotein, and the hCG β-subunit was prepared. The construct shown in FIG. 3 was digested with BspMI and BamHI and the small fragment that was produced was replaced with the fragment obtained from pKBM-hCGβ′ (31) by digestion with BamI and BamHI to create the construct shown in FIG. 6 . XhoI-BamHI fragment obtained from the resulting construct was ligated into the pCI′ expression vector using the XhoI-BamHI sites to create pCI′-Jun-hCGβ′. As noted earlier, it would not be necessary to use pCI′ for this purpose. pSVL has the appropriate restriction sites and would permit expression of the protein in COS-7 cells.

PCI′-Fos-α and pCI-Jun-hCGβ′ were co-transfected into CHO cells using a calcium phosphate method as described (31) to cause the secretion of heterodimers comprised of Fos-a and Jun-hCGβ′. The heterodimers were recognized by monoclonal antibodies to the hCG α- and β-subunits A113 and B112, respectively (45,46). These specific antibodies are not required to measure the presence of heterodimers in the cell culture media and nearly any monoclonal or polyclonal antibodies that have epitopes on the surface of hCG α- and β-subunits that does not involve the N-terminus of the α- or β-subunits will be adequate. The Fos-α/Jun-hCGβ′ heterodimer stimulated signal transduction (cyclic AMP accumulation) in CHO cells that express the rat LH receptor with approximately the same potency as hCG (FIG. 7 ). This showed that the addition of the dimerization domains to the N-termini of both subunits did not adversely affect the biological activity of hCG.

This construct inhibited binding of 125I-hCG to cells that express LH receptors with approximately equal potency as hCG that had been purified from urine ( FIG. 8 ) indicating that the presence of the Fos and Jun sequences on the N-termini of the subunits did not interfere with receptor interaction. Methods for monitoring binding of radioiodinated hCG to LH receptors have been described previously (31,33,45-48) and are well-known in the art.

EXAMPLE 2

Preparation and Characterization of Fos-Jun hCGαδ2, an hCG Analog Containing the Dimerization Domain of Fos Attached to the N-terminus of the α-subunit Lacking the Glycosylation Signal at α-subunit Residue 52 and the Dimerization Domain of Jun Attached to the N-terminus of the β-subunit

Removal of the oligosaccharide normally found on the human α-subunit at residue 52 reduces the ability of the α-subunit analog to combine with the hCG β-subunit (10). This example shows that addition of the Fos dimerization domain to an α-subunit analog lacking the glycosylation signal responsible for adding an oligosaccharide at residue 52 (Fos-αδ52) facilitated formation of heterodimers with Jun-hCGβ′.

A construct encoding the human α-subunit lacking the glycosylation signal at residue 52 was prepared by PCR mutagenesis. Oligonucleotides 739 and 839 ( FIG. 4 ) were used as primers and pKBM-α (31) as template to create an α-subunit construct (pMB507) encoding a glutamine at residue 52 and to introduce BglII and SpeI restriction endonuclease sites. A second PCR was performed using oligonucleotides 850 and 851 ( FIG. 4 ) as primers and pKBM-α (31) as template to create an α-subunit construct encoding an aspartic acid at residue 52 and a glutamine at residue 78. The BglII-SpeI fragment of this construct was subcloned into the BglII-SpeI sites of pMB507 to create an α-subunit construct encoding an aspartic acid corresponding to human α-subunit residue 52. The coding sequence of this mutation ( FIG. 9 ) was confirmed by dideoxy DNA sequencing. Although this sequence also adds silent restriction sites for BglII and SpeI to facilitate preparation of additional mutants, these are not needed to express an analog lacking the oligosaccharide at amino acid 52. Construction of the vector encoding Fos-αδ52 was similar to that encoding Fos-α except that the construct encoding the αδ52-subunit ( FIG. 9 ) was used in place of that encoding the α-subunit to create the sequence shown in FIG. 10 .

Co-expression of Fos-αδ52 and Jun-βsubunits in COS-7 cells led to secretion of heterodimer that could be readily detected in a sandwich radioimmunoassay (41) using monoclonal antibodies A113 and B112 to the α- and β-subunits of hCG. Under these same conditions, much lower amounts of heterodimer were obtained by co-expression of αδ52 and hCG-β subunits lacking the Fos and Jun dimerization domain in COS-7 cells. This showed that the presence of the Fos and Jun sequences at the N-termini of the αδ52- and β-subunits facilitated dimer formation. These results are shown in Table 1.

TABLE 1
Formation of hCG heterodimers in which
the α-subunit is missing an glycosylation
signal needed for efficient subunit combination.
Subunit Combination    Amount of Heterodimer*
No heterodimer (blank) 2554 ± 215
hCG α + hCG β          15281 ± 493
Fos-αδ52 + Jun-hCGβ′   25506 ± 750
*Values represent the results of sandwich immunoassays in which the analyte was captured using an anti-α-subunit antibody (A113) and detected using a radioiodinated anti-β-subunit antibody (B112). The amount of culture media used in each assay was identical (50 μl). the higher the number of counts bound in the assay, the greater the amount of heterodimer. The presence of the Fos-Jun dimerization domain increased the ability of the deglycosylated α-subunit to combine with
# hCG β-subunit to at least as high a level as that seen for hCG.

EXAMPLE 3

Preparation and Characterization of Fos-Jun hCG Analogs Containing the Dimerization Domain of Fos Attached to the N-terminus of the α-subunit and the Dimerization Domain of Jun Attached to the N-terminus of the β-subunit Lacking the Seatbelt or with a Seatbelt that Cannot be Latched

The seatbelt is known to be essential for heterodimer formation. Mutations that disrupt the seatbelt or disrupt the seatbelt latch prevent subunit combination (49). Use of a dimerization domain can enable the formation of glycoprotein hormone analogs that lack the seatbelt and that are able to stimulate signal transduction.

The coding sequence of hCG β-subunit was modified to eliminate the seatbelt latch by replacing Cys26 with alanine. Some other analogs were prepared in which the coding sequence was truncated after the codon for amino acid 92. In addition, to increase the probability that the two subunits would be held together in the heterodimer lacking a properly closed seatbelt in the same orientation as they would be in hCG, an intersubunit disulfide was engineered between the two subunits. This disulfide was placed between the two cysteine knots corresponding to residue 31 from the α-subunit and residue 38 from the β-subunit. Residue 31 is already a cysteine in the α-subunit and normally forms a disulfide with the cysteine at α-subunit residue 7. Changing Cys7 to alanine, provided a free disulfide from the α-subunit for use in the intersubunit disulfide. It's counterpart in the β-subunit was created by changing Tyr37 to cysteine.

The coding sequences of Fos-αC7A, Jun-hCGβ′Y37C, Jun-hCGβ′Y37C/C26A, and Jun-hCGβ′Y37C/C26A5Seatbelt are illustrated in FIGS. 11 , 12 , 13 , and 14 , respectively. These were prepared using a combination of PCR and cassette mutagenesis starting with constructs that have already been described. Fos-αC7A ( FIG. 11 ) was prepared by taking advantage of the fact that the construct encoding Fos-α contains HindIII and BspEI endonuclease restriction sites on either side of the codon corresponding to human α-subunit Cys7. Fos-αC7A was prepared by replacing the small HindIII-BspEI fragment of the coding vector for Fos-α with a cassette prepared from oligonucleotides 1053 and 1054 (FIG. 4 ). The coding sequence of Jun-hCGβ′Y37C ( FIG. 12 ) was prepared by taking advantage of the fact that the pKBM-hCGβ′ (31) contains NgoMI and PstI endonuclease restriction sites surrounding the codon to be changed (i.e., hCG β-subunit Tyr37). Jun-hCGβ′Y37C was prepared in two steps. First, the small NgoMI-PstI site in pKBM-hCGβ′ was replaced with a cassette prepared by annealing oligonucleotides 845 and 877 (FIG. 4 ). Second, the fragment of pKBM-hCGβ′ between the BanI and BamHI sites was cloned into the BspMI-BamHI sites of the vector illustrated in FIG. 3 to create the coding sequence of Jun-hCGβ′Y37C. The coding sequence of Jun-hCGβ′Y37C/C26A ( FIG. 13 ) was prepared using oligonucleotides 1026 and 1027 (FIG. 4 ). These were annealed and filled-in to create a cassette having AvrII and NgoMI restriction sites at its ends. This was digested with AvrII and NgoMI and the resulting fragment was cloned into the AvrII-NgoMI fragment of Jun-hCGβ′Y37C. The coding sequence of Jun-hCGβ′Y37C/C26A892 ( FIG. 14 ) was prepared by replacing the XhoI-PvuII fragment of a truncated hCG β-subunit construct with that from Jun-hCGβ′Y37C/C26A. The truncated hCG β-subunit construct had been prepared in two steps. First, the PvuII-BamHI fragment was replaced with a cassette prepared by annealing and filling-in oligonucleotides 435 and 436 (FIG. 4 ). This cassette was digested with PvuII and BamHI sites and cloned into the PvuII-BamHI fragment of pKBM-hCG β′ (31). This created a BssHII site at the codons for hCG β-subunit amino acids 90-92. The truncated hCG β-subunit was prepared by replacing the BssHII-BamHI fragment of this construct with a cassette prepared by annealing oligonucleotides 837 and 838 (FIG. 4 ).

Fos-αC7A was co-expressed in CHO and/or COS-7 cells with Jun-hCGβ′Y37C, Jun-hCGβ′Y37C/C26A, or Jun-hCGβ′Y37C/C26Aδ92 to yield heterodimers Fos-Jun-hCG-SS, Fos-Jun-hCG-SS-δlatch, or Fos-Jun-hCG-SS-δseatbelt. The heterodimers were readily detected in assays employing A113 and 125 I-B112 for capture and detection, respectively. The activities of Fos-Jun-hCG-SS and Fos-Jun-hCG-SS-δseatbelt were determined in signal transduction assays (FIG. 7 ). The presence of the second intersubunit disulfide in Fos-Jun-hCG-SS reduced the activity of Fos-Jun-hCG slightly in signal transduction assays ( FIG. 7 ) and in receptor binding assays ( FIG. 8 ) as can be seen by comparing the activities of and Fos-Jun-hCG in both assays. The analog lacking the seatbelt was much less active than that of hCG, Fos-Jun-hCG, and Fos-Jun-hCG-SS indicating that the seatbelt had a substantial influence on the activities of hCG in these assays. However, the presence of the Fos-Jun dimerization enabled production of sufficient heterodimer to be able to detect the activities of the material lacking the seatbelt. Without a dimerization domain, it would have been nearly impossible to prepare sufficient heterodimer lacking the seatbelt to test its activity.

These analogs were also tested in FSH and TSH signal transduction assays. hCG has very low ability to stimulate signal transduction in cells containing FSH or TSH receptors (50). The presence of Fos and Jun did not increase the ability of hCG to elicit signal transduction in cells expressing either FSH ( FIG. 15 ) or TSH receptors (FIG. 16 ). Thus, the presence of the dimerization domain did not alter receptor specificity. In addition, the presence of the disulfide did not influence receptor specificity. The analog lacking the seatbelt had low activity, however, its activity in the FSH and TSH assays was only slightly lower than its activity in the LH receptor signal transduction assays. This shows that the presence of the dimerization domain would not be expected to alter receptor interaction or specificity. However, removing the seatbelt increased the maximal amount of signal transduction that could be obtained in TSH assays (FIG. 16 ).

EXAMPLE 4

Fos-Jun hCG Analogs Containing Domains that can be Cleaved During Synthesis in Eucaryotic Cells

The dimerization domains of the analogs whose sequences are described in FIGS. 5 , 6 , and 9 remain associated with the heterodimers. In some cases such as when the heterodimer is to be used as an antigen or a pharmaceutical compound, it may be desirable to remove the dimerization domain. This can be accomplished by a variety of proteolytic methods including digestion with aminopeptidases and/or endopeptidases. In the latter case it usually necessary to incorporate a specific endopeptidase restriction site between the dimerization sequence and the protein to be produced. Many of these are well-known in the art and include the sequences recognized by enterokinase (i.e., DDDDK, (SEQ ID NO: 34) single letter amino acid code) and FactorXa (i.e., IEGR, (SEQ ID NO: 52) single letter amino acid code). It is also possible to include a furin cleavage sequence in this location as illustrated in FIG. 17 . The protein heterodimer to be produced is expected to form a heterodimer in the lumen of the endoplasmic reticulum and then be cleaved by a furin protease located in a downstream part of the secretion pathway. This strategy has the advantage in that it does not require protease digestion of the secreted product.

EXAMPLE 5

Addition of Dimerization Domains to Other Glycoprotein Hormones

Fos-Jun constructs similar to those described in Example 1 can be prepared from other glycoprotein hormone α- and β-subunits including those of hLH, hFSH, hTSH and other vertebrate glycoprotein hormones. FIG. 17 lists the amino acid sequences of some of these with the presence of the furin cleavage site. Addition of the N-terminal dimerization domains would be expected to increase the efficiency of heterodimer formation, particularly with α- and β-subunit analogs that do not readily dimerize. Production and analysis of these analogs would be similar to that of Fos-Jun hCG. It would involve their expression in eucaryotic cells, measurement in sandwich immunoassays using antibodies to the α-subunit for capture and radiolabeled antibodies to the β-subunit for detection, and assay using CHO cells expressing LH, FSH, or TSH receptors. By analogy to Example 4, it should be possible to include endopeptidase sites to cleave the dimerization domain. It should be noted that the location of the furin site shown is not essential to produce these proteins as heterodimers.

EXAMPLE 6

Addition of Different Dimerization Domains to Enhance the Formation of Glycoprotein Hormone Heterodimers

It is not necessary to use the Fos-Jun dimerization strategy to enhance the formation of heterodimers. Addition of nearly any other dimerization domains should suffice. This includes any coiled-coil pair that forms heterodimers. These would be introduced onto the α- and β-subunits of the glycoprotein hormones in a fashion similar to that used to prepare the Fos-Jun analogs. Alternatively, it would be possible to modify the sequences of the Fos and Jun sequences to create additional coiled-coils. Methods for producing and aligning coiled-coils are well known in the art (51). One could also use the heavy and light chains of the immunoglobulins to promote dimerization. An example of the use of the light chain coupled to the α-subunit and the heavy chain coupled to the β-subunit is illustrated in FIGS. 18 and 19 . This could also be reversed such that the light chain is coupled to the β-subunit and the heavy chain is coupled to the α-subunit. Since the heavy and light chains of the antibodies can be selected to bind to various targets, this approach has the additional advantage of enabling one to direct the heterodimers to particular tissues that contain binding sites for the antibodies. By incorporating an enzyme cleavage site, it would be possible to obtain selected release of the hormones from the antibodies at the site in which they had been localized by the presence of the immunoglobulins. The sequences shown in FIGS. 18 and 19 illustrate furin cleavage sites between the immunoglobulin domains and the α- and β-subunits. These could be replaced by any target-specific cleavage site to promote release of the heterodimeric glycoprotein hormone or hormone analog at a desired location. Further, it would be possible to include a furin cleavage site in only the light chain—α-subunit construct or the heavy chain—β-subunit construct and to include a target-specific cleavage site in the other subunit construct at the location shown in FIGS. 18 or 19 by the furin sites. It should be noted that the constructs illustrated in FIG. 18 will be crosslinked by a disulfide near the junction of the immunoglobulin constant domains with the α- and β-subunits. This disulfide may constrict the conformation of the subunits and reduce their activities. To eliminate this, the cysteine near this junction should be replaced with an alanine. Finally, it should be noted that the immunoglobulins illustrated are from the mouse. This would not be expected to be a requirement for the immunoglobulin domain to facilitate subunit combination or targeting. Thus, one could use immunoglobulin domains from other proteins and from other species. The use of immunoglobulin domains from humans would be an advantage for preparing glycoprotein hormone homodimers for use in humans. These domains would also be expected to enhance the half-lives of hormone analogs such as hLH that are known to have short half-live

EXAMPLE 7

Addition of a Dimerization Domain at the C-terminus of the β-subunit that can Form a Heterodimer with a Dimerization Domain Attached to the N-terminus of the α-subunit

Another method of forming heterodimers of the glycoprotein hormones involves addition of the coding region for a dimerization domain such as the sequence needed for dimerization of Fos or Jun or any other protein heterodimer to the C-terminus of the β-subunit unit. When this protein is expressed with a protein that has a complementary dimerization domain attached to the N-terminal end of the α-subunit, it will also form a heterodimer. An example of a β-subunit analog that can enhance dimerization of hCG analogs that would otherwise dimerize poorly is illustrated in FIG. 20 . This illustrates the hCG β-subunit sequence containing a Jun dimerization domain at its C-terminus. When expressed with an α-subunit construct that encodes a Fos dimerization domain at its N-terminus this will lead to the formation of a heterodimer capable of interacting with LH receptors. α-subunit constructs capable of dimerizing with the β-subunit sequences illustrated in FIG. 20 are illustrated in FIGS. 5 and 10 . These α-constructs have the potential to form an intersubunit disulfide bond with the last two β-subunit Jun analogs illustrated in FIG. 20 . When this intersubunit bond is not desired, it can be eliminated by removing the codons for the amino acid sequence Cys-Gly-Gly (CGG). It should be noted that it is not necessary to use Fos and Jun sequences to augment dimerization. It should also be noted that because the C-terminus of the glycoprotein hormone β-subunits is not needed for their hormone activities and that the N-terminus of the glycoprotein hormone α-subunits is not needed for their hormone activities, this process could be applied to all the glycoprotein hormones. It should also be noted that the presence of the hCG β-subunit C-terminus can be used to extend the half-life of all the circulating hormones. Thus, it would be expected that addition of the C-terminus of the hCG β-subunit to the C-terminus of the other glycoprotein hormone β-subunits would be useful in preparing this type of heterodimers and eliciting heterodimers that would have prolonged half-lives. It would also be expected that heterodimers in which the dimerization domain was crosslinked by a disulfide bond could be prepared by expressing the α-subunit constructs illustrated in FIGS. 5 or 10 with either of the last two β-subunit constructs illustrated in FIG. 20 . This would be expected to stabilize the heterodimer.

FIG. 1 illustrates the coding sequence of the hCG β-subunit cDNA between the XhoI and BamHI sites except that the codons for amino acids 2-8 have been deleted. This sequence contains an NheI restriction site between the codons for alanine and serine (i.e., codons −1 and +1, respectively) and is similar to that described by Slaughter et al. (31). The leader sequence from this vector encodes the same amino acids found in hCG β-subunit and was used to prepare subsequent expression constructs because it enables the proteins to enter the secretion pathway. It should be noted that it is not necessary to use the hCG β-subunit leader for this purpose. Most other known leader sequences can be used to drive secretion.

FIG. 2 illustrates the coding sequence of a vector that encodes the hCG β-subunit signal sequence upstream (5′) of bases that encode serine, cysteine, two glycines, and portions of the Fos dimerization domain (one letter code). While this sequence serves well to elicit formation of homodimers, other sequences are expected to work equally well. Indeed, it is expected that most other amino acid sequences known to participate in heterodimer formation will function as a dimerization domain similar to the sequence illustrated in FIG. 2 . Dimerization domains can be designed to be similar to proteins or portions of proteins that are known to form coiled coils. They can be derived from other proteins known to form heterodimers such as portions of the heavy and light chains of immunoglobulins. It is not essential to use the sequence “cysteine-glycine-glycine” shown at the N-terminus of the protein in FIG. 2 . The sequence “glycine-glycine-cysteine” can also be incorporated at the C-terminal end of the Fos dimerization domain such that the cysteine residue would occupy the position normally occupied by glutamine at residue 5 of the human α-subunit. The cysteine has been incorporated to promote the formation of a disulfide to stabilize the heterodimer.

FIG. 3 illustrates the coding sequence of a vector that encodes the hCG β-subunit signal sequence upstream (5′) of bases that encode serine, cysteine, two glycines, and portions of the Jun dimerization domain (one letter code). While this sequence serves well to elicit formation of homodimers, other sequences are expected to work equally well. Indeed, it is expected that most other amino acid sequences known to participate in heterodimer formation will function as a dimerization domain similar to the sequence illustrated in FIG. 3 . Dimerization domains can be designed to be similar to proteins or portions of proteins that are known to form coiled coils. They can be derived from other proteins known to form heterodimers such as portions of the heavy and light chains of immunoglobulins. It is not essential to use the sequence “cysteine-glycine-glycine” shown at the N-terminus of the protein in FIG. 3 . The sequence “glycine-glycine-cysteine” can also be incorporated at the C-terminal end of the Jun dimerization domain such that the cysteine residue would occupy the position normally occupied by glutamine at residue 6 of the human β-subunit. The cysteine has been incorporated to promote the formation of a disulfide to stabilize the heterodimer.

FIG. 4 illustrates the sequences of oligonucleotides used in this work including primers used to create a cassette that permitted insertion of the Fos and Jun dimerization domain amino acid coding sequences into the construct illustrated in FIG. 1 . Each oligonucleotide was synthesized by standard methods. Oligonucleotides 1002 and 1003 (shown in the positions that they hybridize) were mixed and heated to 95° C. for 2 minutes. Vent DNA polymerase (New England Biolabs, Beverly, Mass.) was added and the reaction allowed to cool slowly to 68° C. and maintained at that temperature for 5 min to permit the fill-in reaction to occur. An aliquot of the reaction was added to a second tube containing primers 1004 and 1005 and the tube was heated to 95° C. for 2 minutes. Vent DNA polymerase was added and the reaction allowed to cycle repeatedly between 55° C. (30 seconds), 72° C. (30 seconds), and 95° C. (30 seconds). After 20 cycles, the DNA was removed and purified by electrophoresis through 2% agarose gels. The band at approximately 174 base pairs was electroeluted from the gel, ethanol precipitated, and digested with NheI and BamHI endonucleases. The resulting fragment was ligated into a vector containing the construct illustrated in FIG. 1 at the NheI and BamHI sites. Similarly, oligonucleotides 1006 and 1007 (shown in the positions that they hybridize) were mixed and heated to 95° C. for 2 minutes. Vent DNA polymerase (New England Biolabs) was added and the reaction allowed to cool slowly to 68° C. and maintained at that temperature for 5 min to permit the fill-in reaction to occur. An aliquot of the reaction was added to a second tube containing primers 1008 and 1009 and the tube was heated to 95° C. for 2 minutes. Vent DNA polymerase was added and the reaction allowed to cycle repeatedly between 55° C. (30 seconds), 72° C. (30 seconds), and 95° C. (30 seconds). After 20 cycles, the DNA was removed and purified by electrophoresis through 2% agarose gels. The band at approximately 174 base pairs was electroeluted from the gel, ethanol precipitated, and digested with NheI and BamHI endonucleases. The resulting fragment was ligated into a vector containing the construct illustrated in FIG. 1 at the NheI and BamHI sites. Use of the other oligonucleotides is described in the Examples.

FIG. 5 shows the coding sequence of the entire Fos-hCG-α-subunit construct. It should be noted that it differs from the native hCG α-subunit by the presence of the hCG β-subunit leader sequence, the presence of the Fos sequence, and the lack of 4 α-subunit amino acids, namely Ala1-Pro2-Asp3-Val4(SEQ ID NO:53). These residues were omitted to facilitate formation of the heterodimer. However, it is possible to retain these residues by inserting a linker between the Fos and α-subunit coding regions. When this linker contains a protease cleavage recognition site (e.g., amino acids arginine-serine-lysine-arginine) and when a similar protease cleavage recognition site is introduced between the Jun sequence and the β-subunit construct described later, the heterodimer that is created will lack its Fos sequence at the N-terminus.

FIG. 6 shows the coding sequence of the entire Jun-hCGβ′-subunit construct. It should be noted that it differs from the native hCG β-subunit by the presence of the Jun sequence and the lack of 6 β-subunit amino acids, namely Ser1-Lys2-Glu3-Pro4-Leu5-Arg6(SEQ ID NO:54). These residues were omitted to facilitate formation of the heterodimer. However, it is possible to retain these residues by inserting a linker between the Jun and β-subunit coding regions. When this linker contains a protease cleavage recognition site and when a similar protease cleavage recognition site is introduced between the Fos sequence and the α-subunit construct described earlier, the heterodimer that is created will lack its Jun sequence at the N-terminus.

FIG. 7 shows that the heterodimer containing the Fos-Jun amino acid sequences at its N-termini can stimulate signal transduction in a similar fashion as hCG. Signal transduction (production of cyclic AMP) was monitored using CHO cells that express rat LH receptors as described (33).

FIG. 8 shows that the heterodimer containing the Fos-Jun amino acid sequences at its N-termini can inhibit the binding of radioiodinated hCG to CHO cells expressing rat LH receptors in a similar fashion as hCG. Receptor binding was monitored by inhibiting the binding of radioiodinated hCG to cells expressing LH receptors as described (33).

FIG. 9 illustrates the sequence of an α-subunit construct that is lacking the glycosylation signal normally found at Asn52 of the mature human α-subunit. This construct can be prepared by anyone skilled in the art of DNA mutagenesis by using polymerase chain reaction or other mutagenesis to introduce BglII and SpeI endonuclease restriction sites into the cDNA for the human α-subunit. This will permit making of the construct illustrated here by cassette mutagenesis between the BglII and SpeI sites. Elimination of the glycosylation signal is illustrated here by replacing the codon for Asn52 with that of Asp. Constructs with this mutation are known to have reduced efficacy for LH receptors (10). However, it is not essential that this specific mutation be prepared to eliminate the oligosaccharide at this location.

FIG. 10 illustrates the sequence of the Fos-α-subunit construct that is lacking the glycosylation signal corresponding to human α-subunit residue 52 caused by substitution of an aspartic acid residue for the asparagine normally found at this residue of the human α-subunit. Unlike human α-subunit that has been deglycosylated by this mutation that combines with hCG β-subunit poorly, the construct shown here combines well with the Jun-hCGβ′-subunit to form a heterodimer that binds to LH receptors.

FIG. 11 illustrates the sequence of the Fos-α-subunit construct in which the cysteine normally found at position 7 of the human α-subunit has been replaced by an alanine. When expressed with the Jun-hCGβ′-subunit construct shown in FIG. 12 , this will cause the formation of an intersubunit disulfide between residues of the cysteine knots.

FIG. 12 illustrates the sequence of the Jun-hCGβ′-subunit in which the tyrosine normally found in the hCG β-subunit at residue 37 has been replaced by a cysteine. When expressed with the construct illustrated in FIG. 11 , the heterodimer that is formed will have an intersubunit between residues of its cysteine knots.

FIG. 13 illustrates the Jun-hCGβ′-Y37C-C26A construct. This construct is similar to that in FIG. 12 except that the codon for cysteine normally found at residue 26 in the hCG β-subunit has been changed to alanine. This will prevent closure of the seatbelt. Expression of this construct along with the construct illustrated in FIG. 11 was shown to cause the formation of a heterodimer even though the heterodimer is unable to latch the seatbelt loop.

FIG. 14 illustrates the Jun-hCGβ′-Y37C-C26A-δ92 construct. This construct is similar to that in FIG. 13 except that the codons for all hCG β-subunit seatbelt residues except 91 and 92 are missing. This construct is also missing the residues in the C-terminus normally found in the hCG β-subunit. Expression of this construct along with the construct illustrated in FIG. 11 was shown to cause the formation of a heterodimer even though the heterodimer lacked the seatbelt loop.

FIG. 15 illustrates the abilities of hFSH, hCG, Fos-Jun-hCG-SS/δseatbelt, and Fos-Jun-hCG-SS to stimulate signal transduction in CHO cells expressing human FSH receptors. This shows that hCG is much less potent than hFSH as expected. However, the absence of the seatbelt causes only a small additional influence on the activity of hCG.

FIG. 16 illustrates the abilities of bovine TSH, hCG, Fos-Jun-hCG-SS/δseatbelt, and Fos-Jun-hCG-SS to stimulate signal transduction in CHO cells expressing human FSH receptors. This shows that hCG is much less potent than TSH as expected. However, the absence of the seatbelt causes only a small additional influence on the activity of hCG.

FIG. 17 illustrates the sequences of constructs of Fos-hCG α-subunit containing a furin cleavage site and the sequences of Jun-hCG β-subunit, Jun-hLH β-subunit, Jun-hFSH β-subunit, Jun-hTSH β-subunit, Jun-hCG/hFSH β-subunit chimera, and Jun-hCG/hTSH β-subunit chimera containing a furin cleavage site. Expression of the α-subunit constructs with the β-subunit constructs is expected to lead to the formation of α/β heterodimers similar to the formation of Fos-Jun-hCG and analogs of Fos-Jun-hCG. Following subunit combination in the lumen of the endoplasmic reticulum, the Fos and Jun dimerization domains are expected to be removed during passage of the heterodimer through the Golgi apparatus and trans-Golgi network as it is being readied for secretion. These constructs can be prepared following the steps used to prepare Fos-α and Jun-β except that the codons for the amino acids in a furin cleavage site (e.g., KSKR) are inserted into the oligonucleotides used to encode the Fos and Jun sequences (i.e., the sequences illustrated in FIG. 3 and FIG. 7 ). The internal hyphens are included to facilitate identification of the portions of the molecule that correspond to the hCG β-subunit leader, Fos or Jun dimerization domains, furin cleavage signal, and mature protein. The hyphens at the ends of the lines indicate that the sequence continues uninterrupted on the next line.

FIG. 18 illustrates the sequences of constructs containing immunoglobulin dimerization domains at their N-termini. When the α-subunit construct and a β-subunit construct are expressed in the same cell, an α/β heterodimer will be formed. When the furin cleavage site is present as illustrated in these sequences, the immunoglobulin domains will be removed. Inclusion of the furin cleavage site in only the α- or β-construct is expected to create a dimer that is held to the immunoglobulin domains through bonds to one subunit.

FIG. 19 illustrates the sequences of constructs containing immunoglobulin dimerization domains at their N-termini. Unlike those in FIG. 18 , these immunoglobulin dimerization domains will not form an intersubunit disulfide.

FIG. 20 illustrates the amino acid sequences of β-subunit constructs containing the dimerization domain from Jun at the carboxyterminus of their dimerization domains. As noted, some of these have the ability to form a disulfide crosslink between the two subunits.

Throughout this application, various publications have been referenced. The disclosures in these publications are incorporated herein by reference in order to more fully describe the state of the art.

APPENDIUM OF REFERENCES

1. Pierce, J. G. and T. F. Parsons. 1981. Glycoprotein hormones: structure and function. Ann.Rev.Biochem. 50:465-495.

2. Moyle, W. R. and R. K. Campbell. 1995. Gonadotropins. In Reproductive endocrinology, surgery, and technology. E. Y. Adashi, J. A. Rock, and Z. Rosenwaks, editors. Lippincott-Raven, Philadelphia. 683-724.

3. Moyle, W. R. and R. K. Campbell. 1995. The Gonadotropins. In Endocrinology. L. J. DeGroot, editor. Saunders, Philadelphia. 230-241.

4. Yen, S. S. C. and R. B. Jaffe. 1986. Reproductive Endocrinology: Physiology, Pathophysiology and Clinical Management. W. B.Saunders, Philadelphia.

5. Adashi, E. Y., J. A. Rock, and Z. Rosenwaks. 1996. Reproductive endocrinology, surgery, and technology. Lippincott-Raven, Philadelphia. 5 pp.

6. DeGroot, L. J. 1995. Endocrinology. W.B.Saunders Company, Philadelphia. 3 pp.

7. Anonymous. 1988. Office of Technology Assessment: Report Brief—Infertility: Medical and Social Choices. Washington, D.C.: OTA, US Congress.

8. Anonymous. 1989. Institute of Medicine and National Research Council, Medically Assisted Conception: an agenda for research. Washington, D.C.: National Academy Press.

9. Moyle, W. R., O. P. Bahl, and L. Marz. 1975. Role of the carbohydrate of human choriogonadotropin in the mechanism of hormone action. J.Biol.Chem. 250:9163-9169.

10. Matzuk, M. M., J. L. Keene, and I. Boime. 1989. Site specificity of the chorionic gonadotropin N-linked oligosaccharides in signal transduction. J.Biol.Chem. 264:2409-2414.

11. Morell, A. G., G. Gregoriadis, I. H. Scheinberg, J. Hickman, and G. Ashwell. 1971. The role of sialic acid in determining the survival of glycoproteins in the circulation. J.Biol.Chem. 246:1461-1467.

12. Baenziger, J. U. and E. D. Green. 1988. Pituitary glycoprotein hormone oligosaccharides: structure, synthesis and function of the asparagine-linked oligosaccharides on lutropin, follitropin and thyrotropin. Biochim.Biophys.Acta. 947:287-306.

13. Fiete, D., V. Srivastava, O. Hindsgaul, and J. U. Baenziger. 1991. A hepatic reticuloendothelial cell receptor specific for SO4-4GalNAc (1,4GlcNAc (1,2Man(that mediates rapid clearance of lutropin. Cell 67:1103-1110.

14. Matzuk, M. M. and I. Boime. 1988. Site-specific mutagenesis defines the intracellular role of the asparagine-linked oligosaccharides of chorionic gonadotropin (-subunit. J.Biol.Chem. 263:17106-17111.

15. Matzuk, M. M. and I. Boime. 1988. The role of the asparagine-linked oligosaccharides of the (-subunit in the secretion and assembly of human chorionic gonadotrophin. J.Cell.Biol. 106:1049-1059.

16. Matzuk, M. M. and I. Boime. 1989. Mutagenesis and gene transfer define site-specific roles of the gonadotropin oligosaccharides. Biol.Reprod. 40:48-53.

17. Fiddes, J. C. and K. Talmadge. 1984. Structure, Expression, and Evolution of the genes for the human glycoprotein hormones. In Recent Progress in Hormone Research. Vol 40. R. O. Greep, editor. Academic Press, New York. 43-78.

18. Talmadge, K., N. C. Vamvakopoulos, and J. C. Fiddes. 1984. Evolution of the genes for the beta subunits of human chorionic gonadotropin and luteinizing hormone. Nature 307:37-40.

19. Fiddes, J. C. and H. M. Goodman. 1979. Isolation cloning and sequence analysis of the cDNA for the (-subunit of human chorionic gonadotropin. Nature. 281:351-356.

20. Fiddes, J. C. and H. M. Goodman. 1980. The cDNA for the (-subunit of human chorionic gonadotropin suggests evolution of a gene by readthrough into the 3′-untranslated region. Nature. 286:684-687.

21. Fiddes, J. C. and H. M. Goodman. 1981. The gene encoding the common alpha subunit of the four human glycoprotein hormones. J.Mol.Appl.Genet. 1:3-18.

22. Lapthorn, A. J., D. C. Harris, A. Littlejohn, J. W. Lustbader, R. E. Canfield, K. J. Machin, F. J. Morgan, and N. W. Isaacs. 1994. Crystal structure of human chorionic gonadotropin. Nature 369:455-461.

23. Wu, H., J. W. Lustbader, Y. Liu, R. E. Canfield, and W. A. Hendrickson. 1994. Structure of human chorionic gonadotropin at 2.6Å resolution from MAD analysis of the selenomethionyl protein. Structure 2:545-558.

24. Sun, P. D. and D. R. Davies. 1995. The cysteine-knot growth-factor superfamily. Annu.Rev.Biophys.Biomol.Struct. 24:269-291.

25. Ruddon, R. W., S. A. Sherman, and E. Bedows. 1996. Protein folding in the endoplasmic reticulum: lessons from the human chorionic gonadotropin (-subunit. Prot.Sci. 8:1443-1452.

26. Keutmann, H. T., M. C. Charlesworth, K. A. Mason, T. Ostrea, L. Johnson, and R. J. Ryan. 1987. A receptor-binding region in human choriogonadotropin/lutropin beta subunit. Proc.Natl.Acad.Sci.USA 84:2038-2042.

27. Santa Coloma, T. A., B. Dattatreyamurty, and L. E. Reichert, Jr. 1990. A synthetic peptide corresponding to human FSH ?-subunit 33-53 binds to FSH receptor stimulates basal estradiol synthesis and is a partial antagonist of FSH. Biochemistry. 29:1194-1200.

28. Santa Coloma, T. A. and L. E. Reichert, Jr. 1990. Identification of a follicle-stimulating hormone receptor-binding region in hFSH-(81-95) using synthetic peptides. J.Biol.Chem. 265:5037-5042.

29. Schneyer, A. L., P. M. Sluss, J. S. Huston, R. J. Ridge, and L. E. Reichert, Jr. 1988. Identification of a receptor binding region on the ?-subunit of human follicle-stimulating hormone. Biochemistry. 27:666-671.

30. Reddy, V. B., A. K. Beck, A. J. Garramone, V. Vellucci, J. Lustbader, and E. G. Bernstein. 1985. Expression of human choriogonadotropin in monkey cells using a single simian virus 40 vector. Proc.Natl.Acad.Sci.USA 82:3644-3648.

31. Campbell, R. K., D. M. Dean Emig, and W. R. Moyle. 1991. Conversion of human choriogonadotropin into a follitropin by protein engineering. Proc.Natl.Acad.Sci.USA 88:760-764.

32. Moyle, W. R., M. M. Matzuk, R. K. Campbell, E. Cogliani, D. M. Dean Emig, A. Krichevsky, R. W. Barnett, and I. Boime. 1990. Localization of residues that confer antibody binding specificity using human chorionic gonadotropin/luteinizing hormone beta subunit chimeras and mutants. J.Biol.Chem. 265:8511-8518.

33. Moyle, W. R., R. K. Campbell, R. V. Myers, M. P. Bernard, Y. Han, and X. Wang. 1994. Co-evolution of ligand-receptor pairs. Nature 368:251-255.

34. Matzuk, M. M., M. Krieger, C. L. Corless, and I. Boime. 1987. Effects of preventing β-glycosylation on the secretion of human chorionic gonadotropin in Chinese hamster ovary cells. Proc.Natl.Acad.Sci.USA 84:6354-6358.

35. Matzuk, M. M., C. M. Kornmeier, G. K. Whitfield, I. A. Kourides, and I. Boime. 1988. The glycoprotein (-subunit is critical for secretion and stability of the human thyrotropin (-subunit [published erratum appears in Mol Endocrinol 1988:713]. Mol.Endocrinol. 2:95-100.

36. Kaetzel, D. M., J. K. Browne, F. Wondisford, T. M. Nett, A. R. Thomason, and J. H. Nilson. 1985. Expression of biologically active bovine luteinizing hormone in Chinese hamster ovary cells. Proc.Natl.Acad.Sci.USA 82:7280-7283.

37. Kaetzel, D. M. and J. H. Nilson. 1988. Methotrexate-induced amplification of the bovine lutropin genes in Chinese hamster ovary cells. Relative concentration of the alpha and beta subunits determines the extent of heterodimer assembly. Journal of Biological Chemistry 263:6344-6351.

38. Maniatis, T., E. F. Fritsch, and J. Sambrook. 1989. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.

39. Ausubel, F. M., R. Brent, R. E. Kingston, R. E. Moore, J. G. Seidman, J. A. Smith, and K. Struhl. 1987. Current protocols in molecular biology. Green Publishing Associates and Wiley-Interscience, New York.

40. Kriegler, M. 1990. Gene Transfer and Expression: A Laboratory Manual. Stockton Press, New York.

41. Moyle, W. R., P. H. Ehrlich, and R. E. Canfield. 1982. Use of monoclonal antibodies to hCG subunits to examine the orientation of hCG in the hormone-receptor complex. Proc.Natl.Acad.Sci.USA 79:2245-2249.

42. Slaughter, S., Y. H. Wang, R. V. Myers, and W. R. Moyle. 1995. The lutropin (-subunit N-terminus facilitates subunit combination by offsetting the inhibitory effects of residues needed for LH activity. Mol.Cell.Endocrinol. 112:21-25.

43. Keutmann, H. T. and D. A. Rubin. 1993. A subunit interaction site in human luteinizing hormone: identification by photoaffinity cross-linking. Endocrinology 132:1305-1312.

44. Sugahara, T., M. R. Pixley, S. Minami, E. Perlas, D. Ben-Menahem, A. J. W. Hsueh, and I. Boime. 1995. Biosynthesis of a biologically active single peptide chain containing the human common (and chorionic gonadotropin (subunits in tandem. Proc.Natl.Acad.Sci.USA 92:2041-2045.

45. Cosowsky, L., S. N. V. Rao, G .J. Macdonald, H. Papkoff, R. K. Campbell, and W. R. Moyle. 1995. The groove between the (-and (-subunits of hormones with lutropin (LH) activity appears to contact the LH receptor and its conformation is changed during hormone binding. J.Biol.Chem. 270:20011-20019.

46. Moyle, W. R., R. K. Campbell, S. N. V. Rao, N. G. Ayad, M. P. Bernard, Y. Han, and Y. Wang. 1995. Model of human chorionic gonadotropin (hCG) and lutropin receptor (LHR) interaction that explains signal transduction of the glycoprotein hormones. J. Biol. Chem. 270:20020-20031.

47. Cosowsky, L., W. Lin, Y. Han, M.β. Bernard, R. K. Campbell, and W. R. Moyle. 1997. Influence of subunit interactions on lutropin specificity: implications for studies of glycoprotein hormone function. J.Biol.Chem. 272:3309-3314.

48. Han, Y., M.β. Bernard, and W. R. Moyle. 1996. hCG? Residues 94-96 alter LH activity without appearing to make key receptor contacts. Mol.Cell.Endocrinol. 124:151-161.

49. Suganuma, N., M. M. Matzuk, and I. Boime. 1989. Elimination of disulfide bonds affects assembly and secretion of the human chorionic gonadotropin beta subunit. J.Biol.Chem. 264:19302-19307.

50. Campbell, R. K., E. R. Bergert, Y. Wang, J. C. Morris, and W. R. Moyle. 1997. Chimeric proteins can exceed the sum of their parts: implications for evolution and protein design. Nature Biotech. 15:439-443.

51. Berger, B., D. B. Wilson, E. Wolf, T. Tonchev, M. Milla, and P. S. Kim. 1995. Predicting coiled coils by use of pairwise residue correlations. Proc.Natl.Acad.Sci.USA 92:8259-8263.

52. Fares, F. A., N. Suganuma, K. Nishimori, P. S. LaPolt, A. J. Hsueh, and I. Boime. 1992. Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit. Proc.Natl.Acad.Sci.USA 89:4304-4308.

The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the invention and all such modifications are intended to be included within the scope of the following claims.

90 158 amino acids amino acid unknown unknown peptide NO NO 1Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Ser Cys Arg Pro Ile Asn Ala Thr Leu Ala Val Glu 20 25 30Lys Glu Gly Cys Pro Val Cys Ile Thr Val Asn Thr Thr Ile Cys Ala 35 40 45Gly Tyr Cys Pro Thr Met Thr Arg Val Leu Gln Gly Val Leu Pro Ala 50 55 60Leu Pro Gln Val Val Cys Asn Tyr Arg Asp Val Arg Phe Glu Ser Ile65 70 75 80Arg Leu Pro Gly Cys Pro Arg Gly Val Asn Pro Val Val Ser Tyr Ala 85 90 95Val Ala Leu Ser Cys Gln Cys Ala Leu Cys Arg Arg Ser Thr Thr Asp 100 105 110Cys Gly Gly Pro Lys Asp His Pro Leu Thr Cys Asp Asp Pro Arg Phe 115 120 125Gln Asp Ser Ser Ser Ser Lys Ala Pro Pro Pro Ser Leu Pro Ser Pro 130 135 140Ser Arg Leu Pro Gly Pro Ser Asp Thr Pro Ile Leu Pro Gln145 150 155 587 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 2CTCGAGTCTA GACCCAGCTT AGACAAGGCA GGGGACGCAC CAAGGATGGA GATGTTCCAG 60GGGCTGCTGC TGTTGCTGCT GCTGAGCATG GGCGGGACAT GGGCTAGCTG CCGCCCCATC 120AATGCCACCC TGGCTGTGGA GAAGGAGGGC TGCCCCGTGT GCATCACCGT CAACACCACC 180ATCTGTGCCG GCTACTGCCC CACCATGACC CGCGTGCTGC AGGGCGTCCT CCCGGCCCTG 240CCTCAGGTGG TGTGCAACTA TCGCGATGTG CGCTTCGAGT CCATCCGGCT CCCTGGCTGC 300CCGCGCGGCG TGAACCCCGT GGTCTCCTAC GCCGTGGCTC TCAGCTGTCA ATGTGCACTC 360TGCCGCCGCA GCACCACTGA CTGCGGGGGT CCCAAGGACC ACCCCTTGAC CTGTGATGAC 420CCCCGCTTCC AGGACTCCTC TTCCTCAAAG GCCCCTCCCC CCAGCCTCCC AAGCCCATCC 480CGACTCCCGG GGCCCTCGGA CACCCCGATC CTCCCACAAT AAAGGCTTCT CAATCCGCAA 540GCTGGGGAGC TCGGATCCGC GCGCGTCGAC CCGCGGAGCT CGGATCC 587 587 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 3GAGCTCAGAT CTGGGTCGAA TCTGTTCCGT CCCCTGCGTG GTTCCTACCT CTACAAGGTC 60CCCGACGACG ACAACGACGA CGACTCGTAC CCGCCCTGTA CCCGATCGAC GGCGGGGTAG 120TTACGGTGGG ACCGACACCT CTTCCTCCCG ACGGGGCACA CGTAGTGGCA GTTGTGGTGG 180TAGACACGGC CGATGACGGG GTGGTACTGG GCGCACGACG TCCCGCAGGA GGGCCGGGAC 240GGAGTCCACC ACACGTTGAT AGCGCTACAC GCGAAGCTCA GGTAGGCCGA GGGACCGACG 300GGCGCGCCGC ACTTGGGGCA CCAGAGGATG CGGCACCGAG AGTCGACAGT TACACGTGAG 360ACGGCGGCGT CGTGGTGACT GACGCCCCCA GGGTTCCTGG TGGGGAACTG GACACTACTG 420GGGGCGAAGG TCCTGAGGAG AAGGAGTTTC CGGGGAGGGG GGTCGGAGGG TTCGGGTAGG 480GCTGAGGGCC CCGGGAGCCT GTGGGGCTAG GAGGGTGTTA TTTCCGAAGA GTTAGGCGTT 540CGACCCCTCG AGCCTAGGCG CGCGCAGCTG GGCGCCTCGA GCCTAGG 587 72 amino acids amino acid unknown unknown peptide NO NO 4Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Ser Cys Gly Gly Leu Thr Asp Thr Leu Gln Ala Glu 20 25 30Thr Asp Gln Leu Glu Asp Lys Lys Ser Ala Leu Gln Thr Glu Ile Ala 35 40 45Asn Leu Leu Lys Glu Lys Glu Lys Leu Glu Phe Ile Leu Ala Gly Gln 50 55 60Asp Cys Pro Glu Cys Thr Leu Gln65 70 267 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 5CTCGAGTCTA GACCCAGCTT AGACAAGGCA GGGGACGCAC CAAGGATGGA GATGTTCCAG 60GGGCTGCTGC TGTTGCTGCT GCTGAGCATG GGCGGGACAT GGGCTAGCTG TGGTGGGTTA 120ACCGATACCC TGCAAGCTGA AACTGATCAA CTGGAAGATA AGAAATCTGC TCTGCAAACT 180GAAATCGCTA ATCTGCTGAA AGAGAAGGAA AAGCTTGAGT TCATCCTGGC CGGCCAAGAT 240TGTCCGGAAT GCACGCTACA GGGATCC 267 267 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 6GAGCTCAGAT CTGGGTCGAA TCTGTTCCGT CCCCTGCGTG GTTCCTACCT CTACAAGGTC 60CCCGACGACG ACAACGACGA CGACTCGTAC CCGCCCTGTA CCCGATCGAC ACCACCCAAT 120TGGCTATGGG ACGTTCGACT TTGACTAGTT GACCTTCTAT TCTTTAGACG AGACGTTTGA 180CTTTAGCGAT TAGACGACTT TCTCTTCCTT TTCGAACTCA AGTAGGACCG GCCGGTTCTA 240ACAGGCCTTA CGTGCGATGT CCCTAGG 267 71 amino acids amino acid unknown unknown peptide NO NO 7Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Ser Cys Gly Gly Arg Ile Ala Arg Leu Glu Glu Lys 20 25 30Val Lys Thr Leu Lys Ala Gln Asn Ser Glu Leu Ala Ser Thr Ala Asn 35 40 45Met Leu Arg Glu Gln Val Ala Gln Leu Lys Gln Lys Val Met Gly Leu 50 55 60Arg Pro Arg Cys Leu Ser Arg65 70 267 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 8CTCGAGTCTA GACCCAGCTT AGACAAGGCA GGGGACGCAC CAAGGATGGA GATGTTCCAG 60GGGCTGCTGC TGTTGCTGCT GCTGAGCATG GGCGGGACAT GGGCTAGCTG TGGCGGCCGC 120ATTGCTAGAT TGGAAGAGAA AGTTAAAACT CTGAAGGCCC AAAACAGCGA ACTGGCTTCC 180ACTGCTAATA TGCTGCGTGA ACAAGTCGCT CAACTGAAGC AAAAGGTTAT GGGTTTGCGC 240CCTAGGTGCC TTAGCAGGTA AGGATCC 267 267 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 9GAGCTCAGAT CTGGGTCGAA TCTGTTCCGT CCCCTGCGTG GTTCCTACCT CTACAAGGTC 60CCCGACGACG ACAACGACGA CGACTCGTAC CCGCCCTGTA CCCGATCGAC ACCGCCGGCG 120TAACGATCTA ACCTTCTCTT TCAATTTTGA GACTTCCGGG TTTTGTCGCT TGACCGAAGG 180TGACGATTAT ACGACGCACT TGTTCAGCGA GTTGACTTCG TTTTCCAATA CCCAAACGCG 240GGATCCACGG AATCGTCCAT TCCTAGG 267 51 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 10GAATTCGCTA GCTGTGGTGG GTTAACCGAT ACCCTGCAAG CTGAAACTGA T 51 63 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 11ACCCTGCAAG CTGAAACTGA TCAACTGGAA GATAAGAAAT CTGCTCTGCA AACTGAAATC 60GCT 63 58 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 12TAGACGAGAC GTTTGACTTT AGCGATTAGA CGACTTTCTC TTCCTTTTCG AACTCAAG 58 76 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 13CTTTCTCTTC CTTTTCGAAC TCAAGTAGGA CCGGCCGGTT CTAACAGGCC TTACGTGCGA 60TGTCCCTAGG CTTAAG 76 54 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 14GAATTCGCTA GCTGTGGCGG CCGCATTGCT AGATTGGAAG AGAAAGTTAA AACT 54 63 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 15AGATTGGAAG AGAAAGTTAA AACTCTGAAG GCCCAAAACA GCGAACTGGC TTCCACTGCT 60AAT 63 60 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 16CTTGACCGAA GGTGACGATT ATACGACGCA CTTGTTCAGC GAGTTGACTT CGTTTTCCAA 60 64 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 17AGTTGACTTC GTTTTCCAAT ACCCAAACGC GGGATCCACG GAATCGTCCA TTCCTAGGCT 60TAAG 64 36 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 18GCGCGCCATA TGTTACACCA ACAACGAAAC CAACAC 36 84 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 19TGCTTCTCTA GAGCATATCC AACTCCATTG AGATCTAAGA AGACTATGTT GGTCCAAAAG 60CAAGTCACTA GTGAGTCCAC TTGC 84 60 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 20CCATTGAGAT CTAAGAAGAC TATGTTGGTC CAAAAGGACG TCACTAGTGA GTCCACTTGC 60 45 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 21ACAAGTACTG CAGTGACAAG CAGTGTGTTG CTCCACTTTG AAACC 45 32 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 22AGCTTGAGTT CATCCTGGCC GGCCAAGATG CT 32 32 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 23CCGGAGCATC TTGGCCGGCC AGGATGAACT CA 32 34 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 24CCGGCTGTTG TCCTACCATG ACACGTGTGC TGCA 34 26 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 25GCACACGTGT CATGGTAGGA CAACAG 26 62 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 26CTGCGTCCTA GGTGTCGTCC TATTAATGCT ACTCTGGCTG TTGAGAAGGA AGGTTGTCCT 60GT 62 63 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 27ACAATAGCCG GCACAGATGG TAGTGTTAAC AGTAATGGCC ACAGGACAAC CTTCCTTCTC 60AAC 63 69 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 28GTGGCTCTCA GCTGTCAATG CGCGCTCTGC CGCAGATCTA CCACTGACTG CGGGGTCCCT 60AAGGACCAC 69 72 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 29CCACACGGAT CCGAGCTCTT AGCGGGGGTC ATCACAGGTC AAGGGGTGGT CCTTAGGGAC 60CCCGCAGTCA GT 72 12 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 30CGCGCTTTAA AG 12 12 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 31GATCCTTTAA AG 12 151 amino acids amino acid unknown unknown peptide NO NO 32Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Ser Cys Gly Gly Leu Thr Asp Thr Leu Gln Ala Glu 20 25 30Thr Asp Gln Leu Glu Asp Lys Lys Ser Ala Leu Gln Thr Glu Ile Ala 35 40 45Asn Leu Leu Lys Glu Lys Glu Lys Leu Glu Phe Ile Leu Ala Gly Gln 50 55 60Asp Cys Pro Glu Cys Thr Leu Gln Glu Asn Pro Phe Phe Ser Gln Pro65 70 75 80Gly Ala Pro Ile Leu Gln Cys Met Gly Cys Cys Phe Ser Arg Ala Tyr 85 90 95Pro Thr Pro Leu Arg Ser Lys Lys Thr Met Leu Val Gln Lys Asn Val 100 105 110Thr Ser Glu Ser Thr Cys Cys Val Ala Lys Ser Tyr Asn Arg Val Thr 115 120 125Val Met Gly Gly Phe Lys Val Glu Asn His Thr Ala Cys His Cys Ser 130 135 140Thr Cys Tyr Tyr His Lys Ser145 150 729 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 33CTCGAGTCTA GACCCAGCTT AGACAAGGCA GGGGACGCAC CAAGGATGGA GATGTTCCAG 60GGGCTGCTGC TGTTGCTGCT GCTGAGCATG GGCGGGACAT GGGCTAGCTG TGGTGGGTTA 120ACCGATACCC TGCAAGCTGA AACTGATCAA CTGGAAGATA AGAAATCTGC TCTGCAAACT 180GAAATCGCTA ATCTGCTGAA AGAGAAGGAA AAGCTTGAGT TCATCCTGGC CGGCCAAGAT 240TGTCCGGAAT GCACGCTACA GGAAAACCCA TTCTTCTCCC AGCCGGGTGC CCCAATACTT 300CAGTGCATGG GCTGCTGCTT CTCTAGAGCA TATCCCACTC CACTAAGGTC CAAGAAGACG 360ATGTTGGTCC AAAAGAACGT CACCTCAGAG TCCACTTGCT GTGTAGCTAA ATCATATAAC 420AGGGTCACAG TAATGGGGGG TTTCAAAGTG GAGAACCACA CGGCGTGCCA CTGCAGTACT 480TGTTATTATC ACAAATCTTA AATGTTTTAC CAAGTGCTGT CTTGATGACT GCTGATTTTC 540TGGAATGGAA AATTAAGTTG TTTAGTGTTT ATGGCTTTGT GAGATAAAAC TCTCCTTTTC 600CTTACCATAC CACTTTGACA CGCTTCAAGG ATATACTGCA GCTTTACTGC CTTCCTCCTT 660ATCCTACAGT ACAATCAGCA GTCTAGTTCT TTTCATTTGG AATGAATACA GCATTAAGCT 720GGGGGATCC 729 729 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 34GAGCTCAGAT CTGGGTCGAA TCTGTTCCGT CCCCTGCGTG GTTCCTACCT CTACAAGGTC 60CCCGACGACG ACAACGACGA CGACTCGTAC CCGCCCTGTA CCCGATCGAC ACCACCCAAT 120TGGCTATGGG ACGTTCGACT TTGACTAGTT GACCTTCTAT TCTTTAGACG AGACGTTTGA 180CTTTAGCGAT TAGACGACTT TCTCTTCCTT TTCGAACTCA AGTAGGACCG GCCGGTTCTA 240ACAGGCCTTA CGTGCGATGT CCTTTTGGGT AAGAAGAGGG TCGGCCCACG GGGTTATGAA 300GTCACGTACC CGACGACGAA GAGATCTCGT ATAGGGTGAG GTGATTCCAG GTTCTTCTGC 360TACAACCAGG TTTTCTTGCA GTGGAGTCTC AGGTGAACGA CACATCGATT TAGTATATTG 420TCCCAGTGTC ATTACCCCCC AAAGTTTCAC CTCTTGGTGT GCCGCACGGT GACGTCATGA 480ACAATAATAG TGTTTAGAAT TTACAAAATG GTTCACGACA GAACTACTGA CGACTAAAAG 540ACCTTACCTT TTAATTCAAC AAATCACAAA TACCGAAACA CTCTATTTTG AGAGGAAAAG 600GAATGGTATG GTGAAACTGT GCGAAGTTCC TATATGACGT CGAAATGACG GAAGGAGGAA 660TAGGATGTCA TGTTAGTCGT CAGATCAAGA AAAGTAAACC TTACTTATGT CGTAATTCGA 720CCCCCTAGG 729 204 amino acids amino acid unknown unknown peptide NO NO 35Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Ser Cys Gly Gly Arg Ile Ala Arg Leu Glu Glu Lys 20 25 30Val Lys Thr Leu Lys Ala Gln Asn Ser Glu Leu Ala Ser Thr Ala Asn 35 40 45Met Leu Arg Glu Gln Val Ala Gln Leu Lys Gln Lys Val Met Gly Leu 50 55 60Arg Pro Arg Cys Arg Pro Ile Asn Ala Thr Leu Ala Val Glu Lys Glu65 70 75 80Gly Cys Pro Val Cys Ile Thr Val Asn Thr Thr Ile Cys Ala Gly Tyr 85 90 95Cys Pro Thr Met Thr Arg Val Leu Gln Gly Val Leu Pro Ala Leu Pro 100 105 110Gln Val Val Cys Asn Tyr Arg Asp Val Arg Phe Glu Ser Ile Arg Leu 115 120 125Pro Gly Cys Pro Arg Gly Val Asn Pro Val Val Ser Tyr Ala Val Ala 130 135 140Leu Ser Cys Gln Cys Ala Leu Cys Arg Arg Ser Thr Thr Asp Cys Gly145 150 155 160Gly Pro Lys Asp His Pro Leu Thr Cys Asp Asp Pro Arg Phe Gln Asp 165 170 175Ser Ser Ser Ser Lys Ala Pro Pro Pro Ser Leu Pro Ser Pro Ser Arg 180 185 190Leu Pro Gly Pro Ser Asp Thr Pro Ile Leu Pro Gln 195 200 725 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 36CTCGAGTCTA GACCCAGCTT AGACAAGGCA GGGGACGCAC CAAGGATGGA GATGTTCCAG 60GGGCTGCTGC TGTTGCTGCT GCTGAGCATG GGCGGGACAT GGGCTAGCTG TGGCGGCCGC 120ATTGCTAGAT TGGAAGAGAA AGTTAAAACT CTGAAGGCCC AAAACAGCGA ACTGGCTTCC 180ACTGCTAATA TGCTGCGTGA ACAAGTCGCT CAACTGAAGC AAAAGGTTAT GGGTTTGCGC 240CCTAGGTGCC GCCCCATCAA TGCCACCCTG GCTGTGGAGA AGGAGGGCTG CCCCGTGTGC 300ATCACCGTCA ACACCACCAT CTGTGCCGGC TACTGCCCCA CCATGACCCG CGTGCTGCAG 360GGCGTCCTCC CGGCCCTGCC TCAGGTGGTG TGCAACTACC GCGATGTGCG CTTCGAGTCC 420ATCCGGCTCC CTGGCTGCCC GCGCGGCGTG AACCCCGTGG TCTCCTACGC CGTGGCTCTC 480AGCTGTCAAT GTGCACTCTG CCGCCGCAGC ACCACTGACT GCGGGGGTCC CAAGGACCAC 540CCCTTGACCT GTGATGACCC CCGCTTCCAG GACTCCTCTT CCTCAAAGGC CCCTCCCCCC 600AGCCTTCCAA GCCCATCCCG ACTCCCGGGG CCCTCGGACA CCCCGATCCT CCCACAATAA 660AGGCTTCTCA ATCCGCAAGC TGGGGAGCTC GGATCCGCGC GCGTCGACCC GCGGAGCTCG 720GATCC 725 725 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 37GAGCTCAGAT CTGGGTCGAA TCTGTTCCGT CCCCTGCGTG GTTCCTACCT CTACAAGGTC 60CCCGACGACG ACAACGACGA CGACTCGTAC CCGCCCTGTA CCCGATCGAC ACCGCCGGCG 120TAACGATCTA ACCTTCTCTT TCAATTTTGA GACTTCCGGG TTTTGTCGCT TGACCGAAGG 180TGACGATTAT ACGACGCACT TGTTCAGCGA GTTGACTTCG TTTTCCAATA CCCAAACGCG 240GGATCCACGG CGGGGTAGTT ACGGTGGGAC CGACACCTCT TCCTCCCGAC GGGGCACACG 300TAGTGGCAGT TGTGGTGGTA GACACGGCCG ATGACGGGGT GGTACTGGGC GCACGACGTC 360CCGCAGGAGG GCCGGGACGG AGTCCACCAC ACGTTGATGG CGCTACACGC GAAGCTCAGG 420TAGGCCGAGG GACCGACGGG CGCGCCGCAC TTGGGGCACC AGAGGATGCG GCACCGAGAG 480TCGACAGTTA CACGTGAGAC GGCGGCGTCG TGGTGACTGA CGCCCCCAGG GTTCCTGGTG 540GGGAACTGGA CACTACTGGG GGCGAAGGTC CTGAGGAGAA GGAGTTTCCG GGGAGGGGGG 600TCGGAAGGTT CGGGTAGGGC TGAGGGCCCC GGGAGCCTGT GGGGCTAGGA GGGTGTTATT 660TCCGAAGAGT TAGGCGTTCG ACCCCTCGAG CCTAGGCGCG CGCAGCTGGG CGCCAGCTCG 720GATCC 725 20 amino acids amino acid unknown unknown peptide NO NO 38Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala 20 5 amino acids amino acid unknown unknown peptide NO NO 39Asp Asp Asp Asp Lys1 5 109 amino acids amino acid unknown unknown peptide NO NO 40Met Asp Tyr Tyr Arg Lys Tyr Ala Ala Ile Phe Leu His Val Leu His1 5 10 15Ser Ala Pro Asp Val Gln Asp Cys Pro Glu Cys Thr Leu Gln Glu Asn 20 25 30Pro Phe Phe Ser Gln Pro Gly Ala Pro Ile Leu Gln Cys Met Gly Cys 35 40 45Cys Phe Ser Arg Ala Tyr Pro Thr Pro Leu Arg Ser Lys Lys Thr Met 50 55 60Leu Val Gln Lys Asp Val Thr Ser Glu Ser Thr Cys Cys Val Ala Lys65 70 75 80Ser Tyr Asn Arg Val Thr Val Met Gly Gly Phe Lys Val Glu Asn His 85 90 95Thr Ala Cys His Cys Ser Thr Cys Tyr Tyr His Lys Ser 100 105 631 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 41CTCGAGTCTA GACCCAGCTT GGCAGTCAAC CGCCCTGAAC ACATCCTGCA AAAAGCCCAG 60AGAAAGGAGC GCCATGGATT ACTACAGAAA ATATGCAGCT ATCTTTCTGC ATGTTCTCCA 120TTCCGCTCCT GATGTGCAGG ATTGCCCAGA ATGCACGCTA CAGGAAAACC CATTCTTCTC 180CCAGCCGGGT GCCCCAATAC TTCAGTGCAT GGGCTGCTGC TTCTCTAGAG CATATCCCAC 240TCCACTAAGA TCTAAGAAGA CTATGTTGGT CCAAAAGGAC GTCACTAGTG AGTCCACTTG 300CTGTGTAGCT AAATCATATA ACAGGGTCAC AGTAATGGGG GGTTTCAAAG TGGAGAACCA 360CACGGCGTGC CACTGCAGTA CTTGTTATTA TCACAAATCT TAAATGTTTT ACCAAGTGCT 420GTCTTGATGA CTGCTGATTT TCTGGAATGG AAAATTAAGT TGTTTAGTGT TTATGGCTTT 480GTGAGATAAA ACTCTCCTTT TCCTTACCAT ACCACTTTGA CACGCTTCAA GGATATACTG 540CAGCTTTACT GCCTTCCTCC TTATCCTACA GTACAATCAG CAGTCTAGTT CTTTTCATTT 600GGAATGAATA CAGCATTAAG CTGGGGGATC C 631 631 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 42GAGCTCAGAT CTGGGTCGAA CCGTCAGTTG GCGGCACTTG TGTAGGACGT TTTTCGGGTC 60TCTTTCCTCG CGGTACCTAA TGATGTCTTT TATACGTCGA TAGAAAGACG TACAAGAGGT 120AAGGCGAGGA CTACACGTCC TAACGGGTCT TACGTGCGAT GTCCTTTTGG GTAAGAAGAG 180GGTCGGCCCA CGGGGTTATG AAGTCACGTA CCCGACGACG AAGAGATCTC GTATAGGGTG 240AGGTGATTCT AGATTCTTCT GATACAACCA GGTTTTCCTG CAGTGATGAC TCAGGTGAAC 300GACACATCGA TTTAGTATAT TGTCCCAGTG TCATTACCCC CCAAAGTTTC ACCTCTTGGT 360GTGCCGCACG GTGACGTCAT GAACAATAAT AGTGTTTAGA ATTTACAAAA TGGTTCACGA 420CAGAACTACT GACGACTAAA AGACCTTACC TTTTAATTCA ACAAATCACA AATACCGAAA 480CACTCTATTT TGAGAGGAAA AGGAATGGTA TGGTGAAACT GTGCGAAGTT CCTATATGAC 540GTCGAAATGA CGGAAGGAGG AATAGGATGT CATGTTAGTC GTCAGATCAA GAAAAGTAAA 600CCTTACTTAT GTCGTAATTC GACCCCCTAG G 631 151 amino acids amino acid unknown unknown peptide NO NO 43Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Ser Cys Gly Gly Leu Thr Asp Thr Leu Gln Ala Glu 20 25 30Thr Asp Gln Leu Glu Asp Lys Lys Ser Ala Leu Gln Thr Glu Ile Ala 35 40 45Asn Leu Leu Lys Glu Lys Glu Lys Leu Glu Phe Ile Leu Ala Gly Gln 50 55 60Asp Cys Pro Glu Cys Thr Leu Gln Glu Asn Pro Phe Phe Ser Gln Pro65 70 75 80Gly Ala Pro Ile Leu Gln Cys Met Gly Cys Cys Phe Ser Arg Ala Tyr 85 90 95Pro Thr Pro Leu Arg Ser Lys Lys Thr Met Leu Val Gln Lys Asp Val 100 105 110Thr Ser Glu Ser Thr Cys Cys Val Ala Lys Ser Tyr Asn Arg Val Thr 115 120 125Val Met Gly Gly Phe Lys Val Glu Asn His Thr Ala Cys His Cys Ser 130 135 140Thr Cys Tyr Tyr His Lys Ser145 150 729 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 44CTCGAGTCTA GACCCAGCTT AGACAAGGCA GGGGACGCAC CAAGGATGGA GATGTTCCAG 60GGGCTGCTGC TGTTGCTGCT GCTGAGCATG GGCGGGACAT GGGCTAGCTG TGGTGGGTTA 120ACCGATACCC TGCAAGCTGA AACTGATCAA CTGGAAGATA AGAAATCTGC TCTGCAAACT 180GAAATCGCTA ATCTGCTGAA AGAGAAGGAA AAGCTTGAGT TCATCCTGGC CGGCCAAGAT 240TGTCCGGAAT GCACGCTACA GGAAAACCCA TTCTTCTCCC AGCCGGGTGC CCCAATACTT 300CAGTGCATGG GCTGCTGCTT CTCTAGAGCA TATCCCACTC CACTAAGATC TAAGAAGACT 360ATGTTGGTCC AAAAGGACGT CACTAGTGAG TCCACTTGCT GTGTAGCTAA ATCATATAAC 420AGGGTCACAG TAATGGGGGG TTTCAAAGTG GAGAACCACA CGGCGTGCCA CTGCAGTACT 480TGTTATTATC ACAAATCTTA AATGTTTTAC CAAGTGCTGT CTTGATGACT GCTGATTTTC 540TGGAATGGAA AATTAAGTTG TTTAGTGTTT ATGGCTTTGT GAGATAAAAC TCTCCTTTTC 600CTTACCATAC CACTTTGACA CGCTTCAAGG ATATACTGCA GCTTTACTGC CTTCCTCCTT 660ATCCTACAGT ACAATCAGCA GTCTAGTTCT TTTCATTTGG AATGAATACA GCATTAAGCT 720GGGGGATCC 729 729 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 45GAGCTCAGAT CTGGGTCGAA TCTGTTCCGT CCCCTGCGTG GTTCCTACCT CTACAAGGTC 60CCCGACGACG ACAACGACGA CGACTCGTAC CCGCCCTGTA CCCGATCGAC ACCACCCAAT 120TGGCTATGGG ACGTTCGACT TTGACTAGTT GACCTTCTAT TCTTTAGACG AGACGTTTGA 180CTTTAGCGAT TAGACGACTT TCTCTTCCTT TTCGAACTCA AGTAGGACCG GCCGGTTCTA 240ACAGGCCTTA CGTGCGATGT CCTTTTGGGT AAGAAGAGGG TCGGCCCACG GGGTTATGAA 300GTCACGTACC CGACGACGAA GAGATCTCGT ATAGGGTGAG GTGATTCTAG ATTCTTCTGA 360TACAACCAGG TTTTCCTGCA GTGATGACTC AGGTGAACGA CACATCGATT TAGTATATTG 420TCCCAGTGTC ATTACCCCCC AAAGTTTCAC CTCTTGGTGT GCCGCACGGT GACGTCATGA 480ACAATAATAG TGTTTAGAAT TTACAAAATG GTTCACGACA GAACTACTGA CGACTAAAAG 540ACCTTACCTT TTAATTCAAC AAATCACAAA TACCGAAACA CTCTATTTTG AGAGGAAAAG 600GAATGGTATG GTGAAACTGT GCGAAGTTCC TATATGACGT CGAAATGACG GAAGGAGGAA 660TAGGATGTCA TGTTAGTCGT CAGATCAAGA AAAGTAAACC TTACTTATGT CGTAATTCGA 720CCCCCTAGG 729 151 amino acids amino acid unknown unknown peptide NO NO 46Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Ser Cys Gly Gly Leu Thr Asp Thr Leu Gln Ala Glu 20 25 30Thr Asp Gln Leu Glu Asp Lys Lys Ser Ala Leu Gln Thr Glu Ile Ala 35 40 45Asn Leu Leu Lys Glu Lys Glu Lys Leu Glu Phe Ile Leu Ala Gly Gln 50 55 60Asp Ala Pro Glu Cys Thr Leu Gln Glu Asn Pro Phe Phe Ser Gln Pro65 70 75 80Gly Ala Pro Ile Leu Gln Cys Met Gly Cys Cys Phe Ser Arg Ala Tyr 85 90 95Pro Thr Pro Leu Arg Ser Lys Lys Thr Met Leu Val Gln Lys Asn Val 100 105 110Thr Ser Glu Ser Thr Cys Cys Val Ala Lys Ser Tyr Asn Arg Val Thr 115 120 125Val Met Gly Gly Phe Lys Val Glu Asn His Thr Ala Cys His Cys Ser 130 135 140Thr Cys Tyr Tyr His Lys Ser145 150 729 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 47CTCGAGTCTA GACCCAGCTT AGACAAGGCA GGGGACGCAC CAAGGATGGA GATGTTCCAG 60GGGCTGCTGC TGTTGCTGCT GCTGAGCATG GGCGGGACAT GGGCTAGCTG TGGTGGGTTA 120ACCGATACCC TGCAAGCTGA AACTGATCAA CTGGAAGATA AGAAATCTGC TCTGCAAACT 180GAAATCGCTA ATCTGCTGAA AGAGAAGGAA AAGCTTGAGT TCATCCTGGC CGGCCAAGAT 240GCTCCGGAAT GCACGCTACA GGAAAACCCA TTCTTCTCCC AGCCGGGTGC CCCAATACTT 300CAGTGCATGG GCTGCTGCTT CTCTAGAGCA TATCCCACTC CACTAAGGTC CAAGAAGACG 360ATGTTGGTCC AAAAGAACGT CACCTCAGAG TCCACTTGCT GTGTAGCTAA ATCATATAAC 420AGGGTCACAG TAATGGGGGG TTTCAAAGTG GAGAACCACA CGGCGTGCCA CTGCAGTACT 480TGTTATTATC ACAAATCTTA AATGTTTTAC CAAGTGCTGT CTTGATGACT GCTGATTTTC 540TGGAATGGAA AATTAAGTTG TTTAGTGTTT ATGGCTTTGT GAGATAAAAC TCTCCTTTTC 600CTTACCATAC CACTTTGACA CGCTTCAAGG ATATACTGCA GCTTTACTGC CTTCCTCCTT 660ATCCTACAGT ACAATCAGCA GTCTAGTTCT TTTCATTTGG AATGAATACA GCATTAAGCT 720GGGGGATCC 729 729 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 48GAGCTCAGAT CTGGGTCGAA TCTGTTCCGT CCCCTGCGTG GTTCCTACCT CTACAAGGTC 60CCCGACGACG ACAACGACGA CGACTCGTAC CCGCCCTGTA CCCGATCGAC ACCACCCAAT 120TGGCTATGGG ACGTTCGACT TTGACTAGTT GACCTTCTAT TCTTTAGACG AGACGTTTGA 180CTTTAGCGAT TAGACGACTT TCTCTTCCTT TTCGAACTCA AGTAGGACCG GCCGGTTCTA 240CGAGGCCTTA CGTGCGATGT CCTTTTGGGT AAGAAGAGGG TCGGCCCACG GGGTTATGAA 300GTCACGTACC CGACGACGAA GAGATCTCGT ATAGGGTGAG GTGATTCCAG GTTCTTCTGC 360TACAACCAGG TTTTCTTGCA GTGGAGTCTC AGGTGAACGA CACATCGATT TAGTATATTG 420TCCCAGTGTC ATTACCCCCC AAAGTTTCAC CTCTTGGTGT GCCGCACGGT GACGTCATGA 480ACAATAATAG TGTTTAGAAT TTACAAAATG GTTCACGACA GAACTACTGA CGACTAAAAG 540ACCTTACCTT TTAATTCAAC AAATCACAAA TACCGAAACA CTCTATTTTG AGAGGAAAAG 600GAATGGTATG GTGAAACTGT GCGAAGTTCC TATATGACGT CGAAATGACG GAAGGAGGAA 660TAGGATGTCA TGTTAGTCGT CAGATCAAGA AAAGTAAACC TTACTTATGT CGTAATTCGA 720CCCCCTAGG 729 204 amino acids amino acid unknown unknown peptide NO NO 49Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Ser Cys Gly Gly Arg Ile Ala Arg Leu Glu Glu Lys 20 25 30Val Lys Thr Leu Lys Ala Gln Asn Ser Glu Leu Ala Ser Thr Ala Asn 35 40 45Met Leu Arg Glu Gln Val Ala Gln Leu Lys Gln Lys Val Met Gly Leu 50 55 60Arg Pro Arg Cys Arg Pro Ile Asn Ala Thr Leu Ala Val Glu Lys Glu65 70 75 80Gly Cys Pro Val Cys Ile Thr Val Asn Thr Thr Ile Cys Ala Gly Tyr 85 90 95Cys Pro Thr Met Thr Arg Val Leu Gln Gly Val Leu Pro Ala Leu Pro 100 105 110Gln Val Val Cys Asn Tyr Arg Asp Val Arg Phe Glu Ser Ile Arg Leu 115 120 125Pro Gly Cys Pro Arg Gly Val Asn Pro Val Val Ser Tyr Ala Val Ala 130 135 140Leu Ser Cys Gln Cys Ala Leu Cys Arg Arg Ser Thr Thr Asp Cys Gly145 150 155 160Gly Pro Lys Asp His Pro Leu Thr Cys Asp Asp Pro Arg Phe Gln Asp 165 170 175Ser Ser Ser Ser Lys Ala Pro Pro Pro Ser Leu Pro Ser Pro Ser Arg 180 185 190Leu Pro Gly Pro Ser Asp Thr Pro Ile Leu Pro Gln 195 200 725 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 50CTCGAGTCTA GACCCAGCTT AGACAAGGCA GGGGACGCAC CAAGGATGGA GATGTTCCAG 60GGGCTGCTGC TGTTGCTGCT GCTGAGCATG GGCGGGACAT GGGCTAGCTG TGGCGGCCGC 120ATTGCTAGAT TGGAAGAGAA AGTTAAAACT CTGAAGGCCC AAAACAGCGA ACTGGCTTCC 180ACTGCTAATA TGCTGCGTGA ACAAGTCGCT CAACTGAAGC AAAAGGTTAT GGGTTTGCGC 240CCTAGGTGCC GCCCCATCAA TGCCACCCTG GCTGTGGAGA AGGAGGGCTG CCCCGTGTGC 300ATCACCGTCA ACACCACCAT CTGTGCCGGC TGTTGTCCTA CCATGACACG TGTGCTGCAG 360GGCGTCCTCC CGGCCCTGCC TCAGGTGGTG TGCAACTACC GCGATGTGCG CTTCGAGTCC 420ATCCGGCTCC CTGGCTGCCC GCGCGGCGTG AACCCCGTGG TCTCCTACGC CGTGGCTCTC 480AGCTGTCAAT GTGCACTCTG CCGCCGCAGC ACCACTGACT GCGGGGGTCC CAAGGACCAC 540CCCTTGACCT GTGATGACCC CCGCTTCCAG GACTCCTCTT CCTCAAAGGC CCCTCCCCCC 600AGCCTTCCAA GCCCATCCCG ACTCCCGGGG CCCTCGGACA CCCCGATCCT CCCACAATAA 660AGGCTTCTCA ATCCGCAAGC TGGGGAGCTC GGATCCGCGC GCGTCGACCC GCGGAGCTCG 720GATCC 725 725 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 51GAGCTCAGAT CTGGGTCGAA TCTGTTCCGT CCCCTGCGTG GTTCCTACCT CTACAAGGTC 60CCCGACGACG ACAACGACGA CGACTCGTAC CCGCCCTGTA CCCGATCGAC ACCGCCGGCG 120TAACGATCTA ACCTTCTCTT TCAATTTTGA GACTTCCGGG TTTTGTCGCT TGACCGAAGG 180TGACGATTAT ACGACGCACT TGTTCAGCGA GTTGACTTCG TTTTCCAATA CCCAAACGCG 240GGATCCACGG CGGGGTAGTT ACGGTGGGAC CGACACCTCT TCCTCCCGAC GGGGCACACG 300TAGTGGCAGT TGTGGTGGTA GACACGGCCG ACAACAGGAT GGTACTGTGC ACACGACGTC 360CCGCAGGAGG GCCGGGACGG AGTCCACCAC ACGTTGATGG CGCTACACGC GAAGCTCAGG 420TAGGCCGAGG GACCGACGGG CGCGCCGCAC TTGGGGCACC AGAGGATGCG GCACCGAGAG 480TCGACAGTTA CACGTGAGAC GGCGGCGTCG TGGTGACTGA CGCCCCCAGG GTTCCTGGTG 540GGGAACTGGA CACTACTGGG GGCGAAGGTC CTGAGGAGAA GGAGTTTCCG GGGAGGGGGG 600TCGGAAGGTT CGGGTAGGGC TGAGGGCCCC GGGAGCCTGT GGGGCTAGGA GGGTGTTATT 660TCCGAAGAGT TAGGCGTTCG ACCCCTCGAG CCTAGGCGCG CGCAGCTGGG CGCCTCGAGC 720CTAGG 725 4 amino acids amino acid unknown unknown peptide NO NO 52Ile Glu Gly Arg1 11 amino acids amino acid unknown unknown peptide NO NO 53Ala Leu Ala Pro Arg Ala Ser Pro Val Ala Leu1 5 10 204 amino acids amino acid unknown unknown peptide NO NO 54Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Ser Cys Gly Gly Arg Ile Ala Arg Leu Glu Glu Lys 20 25 30Val Lys Thr Leu Lys Ala Gln Asn Ser Glu Leu Ala Ser Thr Ala Asn 35 40 45Met Leu Arg Glu Gln Val Ala Gln Leu Lys Gln Lys Val Met Gly Leu 50 55 60Arg Pro Arg Cys Arg Pro Ile Asn Ala Thr Leu Ala Val Glu Lys Glu65 70 75 80Gly Cys Pro Val Ala Ile Thr Val Asn Thr Thr Ile Cys Ala Gly Tyr 85 90 95Cys Pro Thr Met Thr Arg Val Leu Gln Gly Val Leu Pro Ala Leu Pro 100 105 110Gln Val Val Cys Asn Tyr Arg Asp Val Arg Phe Glu Ser Ile Arg Leu 115 120 125Pro Gly Cys Pro Arg Gly Val Asn Pro Val Val Ser Tyr Ala Val Ala 130 135 140Leu Ser Cys Gln Cys Ala Leu Cys Arg Arg Ser Thr Thr Asp Cys Gly145 150 155 160Gly Pro Lys Asp His Pro Leu Thr Cys Asp Asp Pro Arg Phe Gln Asp 165 170 175Ser Ser Ser Ser Lys Ala Pro Pro Pro Ser Leu Pro Ser Pro Ser Arg 180 185 190Leu Pro Gly Pro Ser Asp Thr Pro Ile Leu Pro Gln 195 200 725 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 55CTCGAGTCTA GACCCAGCTT AGACAAGGCA GGGGACGCAC CAAGGATGGA GATGTTCCAG 60GGGCTGCTGC TGTTGCTGCT GCTGAGCATG GGCGGGACAT GGGCTAGCTG TGGCGGCCGC 120ATTGCTAGAT TGGAAGAGAA AGTTAAAACT CTGAAGGCCC AAAACAGCGA ACTGGCTTCC 180ACTGCTAATA TGCTGCGTGA ACAAGTCGCT CAACTGAAGC AAAAGGTTAT GGGTTTGCGC 240CCTAGGTGTC GTCCTATTAA TGCTACTCTG GCTGTTGAGA AGGAAGGTTG TCCTGTGGCC 300ATTACTGTTA ACACTACCAT CTGTGCCGGC TGTTGTCCTA CCATGACACG TGTGCTGCAG 360GGCGTCCTCC CGGCCCTGCC TCAGGTGGTG TGCAACTACC GCGATGTGCG CTTCGAGTCC 420ATCCGGCTCC CTGGCTGCCC GCGCGGCGTG AACCCCGTGG TCTCCTACGC CGTGGCTCTC 480AGCTGTCAAT GTGCACTCTG CCGCCGCAGC ACCACTGACT GCGGGGGTCC CAAGGACCAC 540CCCTTGACCT GTGATGACCC CCGCTTCCAG GACTCCTCTT CCTCAAAGGC CCCTCCCCCC 600AGCCTTCCAA GCCCATCCCG ACTCCCGGGG CCCTCGGACA CCCCGATCCT CCCACAATAA 660AGGCTTCTCA ATCCGCAAGC TGGGGAGCTC GGATCCGCGC GCGTCGACCC GCGGAGCTCG 720GATCC 725 725 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 56GAGCTCAGAT CTGGGTCGAA TCTGTTCCGT CCCCTGCGTG GTTCCTACCT CTACAAGGTC 60CCCGACGACG ACAACGACGA CGACTCGTAC CCGCCCTGTA CCCGATCGAC ACCGCCGGCG 120TAACGATCTA ACCTTCTCTT TCAATTTTGA GACTTCCGGG TTTTGTCGCT TGACCGAAGG 180TGACGATTAT ACGACGCACT TGTTCAGCGA GTTGACTTCG TTTTCCAATA CCCAAACGCG 240GGATCCACAG CAGGATAATT ACGATGAGAC CGACAACTCT TCCTTCCAAC AGGACACCGG 300TAATGACAAT TGTGATGGTA GACACGGCCG ACAACAGGAT GGTACTGTGC ACACGACGTC 360CCGCAGGAGG GCCGGGACGG AGTCCACCAC ACGTTGATGG CGCTACACGC GAAGCTCAGG 420TAGGCCGAGG GACCGACGGG CGCGCCGCAC TTGGGGCACC AGAGGATGCG GCACCGAGAG 480TCGACAGTTA CACGTGAGAC GGCGGCGTCG TGGTGACTGA CGCCCCCAGG GTTCCTGGTG 540GGGAACTGGA CACTACTGGG GGCGAAGGTC CTGAGGAGAA GGAGTTTCCG GGGAGGGGGG 600TCGGAAGGTT CGGGTAGGGC TGAGGGCCCC GGGAGCCTGT GGGGCTAGGA GGGTGTTATT 660TCCGAAGAGT TAGGCGTTCG ACCCCTCGAG CCTAGGCGCG CGCAGCTGGG CGCCTCGAGC 720CTAGG 725 15 amino acids amino acid unknown unknown peptide NO NO 57Ser Glu Arg Leu Tyr Ser Gly Leu Pro Arg Leu Glu Ala Arg Gly1 5 10 15 212 amino acids amino acid unknown unknown peptide NO NO 58Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Ser Lys Glu Pro Leu Arg Pro Arg Cys Arg Pro Ile 20 25 30Asn Ala Thr Leu Ala Val Glu Lys Glu Gly Cys Pro Val Cys Ile Thr 35 40 45Val Asn Thr Thr Ile Cys Ala Gly Tyr Cys Pro Thr Met Thr Arg Val 50 55 60Leu Gln Gly Val Leu Pro Ala Leu Pro Gln Val Val Cys Asn Tyr Arg65 70 75 80Asp Val Arg Phe Glu Ser Ile Arg Leu Pro Gly Cys Pro Arg Gly Val 85 90 95Asn Pro Val Val Ser Tyr Ala Val Ala Leu Ser Cys Gln Cys Ala Leu 100 105 110Cys Arg Arg Ser Thr Thr Asp Cys Gly Gly Pro Lys Asp His Pro Leu 115 120 125Thr Cys Asp Asp Pro Arg Phe Gln Asp Ser Ser Ser Ser Lys Ala Pro 130 135 140Pro Pro Ser Leu Pro Ser Pro Ser Arg Leu Pro Gly Pro Ser Asp Thr145 150 155 160Pro Ile Leu Pro Gln Gly Ser Gly Ser Gly Ser Cys Gly Gly Arg Ile 165 170 175Ala Arg Leu Glu Glu Lys Val Lys Thr Leu Lys Ala Gln Asn Ser Glu 180 185 190Leu Ala Ser Thr Ala Asn Met Leu Arg Glu Gln Val Ala Gln Leu Lys 195 200 205Gln Lys Val Met 210 151 amino acids amino acid unknown unknown peptide NO NO 59Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Ser Cys Gly Gly Arg Ile Ala Arg Leu Glu Glu Lys 20 25 30Val Lys Thr Leu Lys Ala Gln Asn Ser Glu Leu Ala Ser Thr Ala Asn 35 40 45Met Leu Arg Glu Gln Val Ala Gln Leu Lys Gln Lys Val Met Gly Leu 50 55 60Arg Pro Arg Cys Arg Pro Ile Asn Ala Thr Leu Ala Val Glu Lys Glu65 70 75 80Gly Cys Pro Val Ala Ile Thr Val Asn Thr Thr Ile Cys Ala Gly Tyr 85 90 95Cys Pro Thr Met Thr Arg Val Leu Gln Gly Val Leu Pro Ala Leu Pro 100 105 110Gln Val Val Cys Asn Tyr Arg Asp Val Arg Phe Glu Ser Ile Arg Leu 115 120 125Pro Gly Cys Pro Arg Gly Val Asn Pro Val Val Ser Tyr Ala Val Ala 130 135 140Leu Ser Cys Gln Cys Ala Leu145 150 508 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 60CTCGAGTCTA GACCCAGCTT AGACAAGGCA GGGGACGCAC CAAGGATGGA GATGTTCCAG 60GGGCTGCTGC TGTTGCTGCT GCTGAGCATG GGCGGGACAT GGGCTAGCTG TGGCGGCCGC 120ATTGCTAGAT TGGAAGAGAA AGTTAAAACT CTGAAGGCCC AAAACAGCGA ACTGGCTTCC 180ACTGCTAATA TGCTGCGTGA ACAAGTCGCT CAACTGAAGC AAAAGGTTAT GGGTTTGCGC 240CCTAGGTGTC GTCCTATTAA TGCTACTCTG GCTGTTGAGA AGGAAGGTTG TCCTGTGGCC 300ATTACTGTTA ACACTACCAT CTGTGCCGGC TGTTGTCCTA CCATGACACG TGTGCTGCAG 360GGCGTCCTCC CGGCCCTGCC TCAGGTGGTG TGCAACTACC GCGATGTGCG CTTCGAGTCC 420ATCCGGCTCC CTGGCTGCCC GCGCGGCGTG AACCCCGTGG TCTCCTACGC CGTGGCTCTC 480AGCTGTCAAT GCGCGCTTTA AAGGATCC 508 508 base pairs nucleic acid unknown unknown DNA (genomic) NO NO 61GAGCTCAGAT CTGGGTCGAA TCTGTTCCGT CCCCTGCGTG GTTCCTACCT CTACAAGGTC 60CCCGACGACG ACAACGACGA CGACTCGTAC CCGCCCTGTA CCCGATCGAC ACCGCCGGCG 120TAACGATCTA ACCTTCTCTT TCAATTTTGA GACTTCCGGG TTTTGTCGCT TGACCGAAGG 180TGACGATTAT ACGACGCACT TGTTCAGCGA GTTGACTTCG TTTTCCAATA CCCAAACGCG 240GGATCCACAG CAGGATAATT ACGATGAGAC CGACAACTCT TCCTTCCAAC AGGACACCGG 300TAATGACAAT TGTGATGGTA GACACGGCCG ACAACAGGAT GGTACTGTGC ACACGACGTC 360CCGCAGGAGG GCCGGGACGG AGTCCACCAC ACGTTGATGG CGCTACACGC GAAGCTCAGG 420TAGGCCGAGG GACCGACGGG CGCGCCGCAC TTGGGGCACC AGAGGATGCG GCACCGAGAG 480TCGACAGTTA CGCGCGAAAT TTCCTAGG 508 155 amino acids amino acid unknown unknown peptide NO NO 62Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Ser Cys Gly Gly Leu Thr Asp Thr Leu Gln Ala Glu 20 25 30Thr Asp Gln Leu Glu Asp Lys Lys Ser Ala Leu Gln Thr Glu Ile Ala 35 40 45Asn Leu Leu Lys Glu Lys Glu Lys Leu Glu Phe Ile Leu Ala Gly Lys 50 55 60Ser Lys Arg Gln Asp Cys Pro Glu Cys Thr Leu Gln Glu Asn Pro Phe65 70 75 80Phe Ser Gln Pro Gly Ala Pro Ile Leu Gln Cys Met Gly Cys Cys Phe 85 90 95Ser Arg Ala Tyr Pro Thr Pro Leu Arg Ser Lys Lys Thr Met Leu Val 100 105 110Gln Lys Asn Val Thr Ser Glu Ser Thr Cys Cys Val Ala Lys Ser Tyr 115 120 125Asn Arg Val Thr Val Met Gly Gly Phe Lys Val Glu Asn His Thr Ala 130 135 140Cys His Cys Ser Thr Cys Tyr Tyr His Lys Ser145 150 155 208 amino acids amino acid unknown unknown peptide NO NO 63Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Ser Cys Gly Gly Arg Ile Ala Arg Leu Glu Glu Lys 20 25 30Val Lys Thr Leu Lys Ala Gln Asn Ser Glu Leu Ala Ser Thr Ala Asn 35 40 45Met Leu Arg Glu Gln Val Ala Gln Leu Lys Gln Lys Val Met Gly Lys 50 55 60Ser Lys Arg Leu Arg Pro Arg Cys Arg Pro Ile Asn Ala Thr Leu Ala65 70 75 80Val Glu Lys Glu Gly Cys Pro Val Cys Ile Thr Val Asn Thr Thr Ile 85 90 95Cys Ala Gly Tyr Cys Pro Thr Met Thr Arg Val Leu Gln Gly Val Leu 100 105 110Pro Ala Leu Pro Gln Val Val Cys Asn Tyr Arg Asp Val Arg Phe Glu 115 120 125Ser Ile Arg Leu Pro Gly Cys Pro Arg Gly Val Asn Pro Val Val Ser 130 135 140Tyr Ala Val Ala Leu Ser Cys Gln Cys Ala Leu Cys Arg Arg Ser Thr145 150 155 160Thr Asp Cys Gly Gly Pro Lys Asp His Pro Leu Thr Cys Asp Asp Pro 165 170 175Arg Phe Gln Asp Ser Ser Ser Ser Lys Ala Pro Pro Pro Ser Leu Pro 180 185 190Ser Pro Ser Arg Leu Pro Gly Pro Ser Asp Thr Pro Ile Leu Pro Gln 195 200 205 159 amino acids amino acid unknown unknown peptide NO NO 64Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Ser Cys Gly Gly Leu Thr Asp Thr Leu Gln Ala Glu 20 25 30Thr Asp Gln Leu Glu Asp Lys Lys Ser Ala Leu Gln Thr Glu Ile Ala 35 40 45Asn Leu Leu Lys Glu Lys Glu Lys Leu Glu Phe Ile Leu Ala Gly Lys 50 55 60Ser Lys Arg Ala Pro Asp Val Gln Asp Cys Pro Glu Cys Thr Leu Gln65 70 75 80Glu Asn Pro Phe Phe Ser Gln Pro Gly Ala Pro Ile Leu Gln Cys Met 85 90 95Gly Cys Cys Phe Ser Arg Ala Tyr Pro Thr Pro Leu Arg Ser Lys Lys 100 105 110Thr Met Leu Val Gln Lys Asn Val Thr Ser Glu Ser Thr Cys Cys Val 115 120 125Ala Lys Ser Tyr Asn Arg Val Thr Val Met Gly Gly Phe Lys Val Glu 130 135 140Asn His Thr Ala Cys His Cys Ser Thr Cys Tyr Tyr His Lys Ser145 150 155 212 amino acids amino acid unknown unknown peptide NO NO 65Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Ser Cys Gly Gly Arg Ile Ala Arg Leu Glu Glu Lys 20 25 30Val Lys Thr Leu Lys Ala Gln Asn Ser Glu Leu Ala Ser Thr Ala Asn 35 40 45Met Leu Arg Glu Gln Val Ala Gln Leu Lys Gln Lys Val Met Gly Lys 50 55 60Ser Lys Arg Ser Lys Glu Pro Leu Arg Pro Arg Cys Arg Pro Ile Asn65 70 75 80Ala Thr Leu Ala Val Glu Lys Glu Gly Cys Pro Val Cys Ile Thr Val 85 90 95Asn Thr Thr Ile Cys Ala Gly Tyr Cys Pro Thr Met Thr Arg Val Leu 100 105 110Gln Gly Val Leu Pro Ala Leu Pro Gln Val Val Cys Asn Tyr Arg Asp 115 120 125Val Arg Phe Glu Ser Ile Arg Leu Pro Gly Cys Pro Arg Gly Val Asn 130 135 140Pro Val Val Ser Tyr Ala Val Ala Leu Ser Cys Gln Cys Ala Leu Cys145 150 155 160Arg Arg Ser Thr Thr Asp Cys Gly Gly Pro Lys Asp His Pro Leu Thr 165 170 175Cys Asp Asp Pro Arg Phe Gln Asp Ser Ser Ser Ser Lys Ala Pro Pro 180 185 190Pro Ser Leu Pro Ser Pro Ser Arg Leu Pro Gly Pro Ser Asp Thr Pro 195 200 205Ile Leu Pro Gln 210 181 amino acids amino acid unknown unknown peptide NO NO 66Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Ser Cys Gly Gly Arg Ile Ala Arg Leu Glu Glu Lys 20 25 30Val Lys Thr Leu Lys Ala Gln Asn Ser Glu Leu Ala Ser Thr Ala Asn 35 40 45Met Leu Arg Glu Gln Val Ala Gln Leu Lys Gln Lys Val Met Gly Lys 50 55 60Ser Lys Arg Ser Arg Glu Pro Leu Arg Pro Trp Cys His Pro Ile Asn65 70 75 80Ala Ile Leu Ala Val Glu Lys Glu Gly Cys Pro Val Cys Ile Thr Val 85 90 95Asn Thr Thr Ile Cys Ala Gly Tyr Cys Pro Thr Met Met Arg Val Leu 100 105 110Gln Ala Val Leu Pro Pro Leu Pro Gln Val Val Cys Thr Tyr Arg Asp 115 120 125Val Arg Phe Glu Ser Ile Arg Leu Pro Gly Cys Pro Arg Gly Val Asp 130 135 140Pro Val Val Ser Phe Pro Val Ala Leu Ser Cys Arg Cys Ala Leu Cys145 150 155 160Arg Arg Ser Thr Ser Asp Cys Gly Gly Pro Lys Asp His Pro Leu Thr 165 170 175Cys Asp His Pro Gln 180 184 amino acids amino acid unknown unknown peptide NO NO 67Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Ser Cys Gly Gly Arg Ile Ala Arg Leu Glu Glu Lys 20 25 30Val Lys Thr Leu Lys Ala Gln Asn Ser Glu Leu Ala Ser Thr Ala Asn 35 40 45Met Leu Arg Glu Gln Val Ala Gln Leu Lys Gln Lys Val Met Gly Ser 50 55 60Lys Glu Pro Leu Arg Lys Ser Lys Arg Asn Ser Cys Glu Leu Thr Asn65 70 75 80Ile Thr Ile Ala Ile Glu Lys Glu Glu Cys Arg Phe Cys Ile Ser Ile 85 90 95Asn Thr Thr Trp Cys Ala Gly Tyr Cys Tyr Thr Arg Asp Leu Val Tyr 100 105 110Lys Asp Pro Ala Arg Pro Lys Ile Gln Lys Thr Cys Thr Phe Lys Glu 115 120 125Leu Val Tyr Glu Thr Val Arg Val Pro Gly Cys Ala His His Ala Asp 130 135 140Ser Leu Tyr Thr Tyr Pro Val Ala Thr Gln Cys His Cys Gly Lys Cys145 150 155 160Asp Ser Asp Ser Thr Asp Cys Thr Val Arg Gly Leu Gly Pro Ser Tyr 165 170 175Cys Ser Phe Gly Glu Met Lys Glu 180 186 amino acids amino acid unknown unknown peptide NO NO 68Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Ser Cys Gly Gly Arg Ile Ala Arg Leu Glu Glu Lys 20 25 30Val Lys Thr Leu Lys Ala Gln Asn Ser Glu Leu Ala Ser Thr Ala Asn 35 40 45Met Leu Arg Glu Gln Val Ala Gln Leu Lys Gln Lys Val Met Gly Ser 50 55 60Lys Glu Pro Leu Arg Gly Lys Ser Lys Arg Phe Cys Ile Pro Thr Glu65 70 75 80Tyr Thr Met His Ile Glu Arg Arg Glu Cys Ala Tyr Cys Leu Thr Ile 85 90 95Asn Thr Thr Ile Cys Ala Gly Tyr Cys Met Thr Arg Asp Ile Asn Gly 100 105 110Lys Leu Phe Leu Pro Lys Tyr Ala Leu Ser Gln Asp Val Cys Thr Tyr 115 120 125Arg Asp Phe Ile Tyr Arg Thr Val Glu Ile Pro Gly Cys Pro Leu His 130 135 140Val Ala Pro Tyr Phe Ser Tyr Pro Val Ala Leu Ser Cys Lys Cys Gly145 150 155 160Lys Cys Asn Thr Asp Tyr Ser Asp Cys Ile His Glu Ala Ile Lys Thr 165 170 175Asn Tyr Cys Thr Lys Pro Gln Lys Ser Tyr 180 185 212 amino acids amino acid unknown unknown peptide NO NO 69Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Ser Cys Gly Gly Arg Ile Ala Arg Leu Glu Glu Lys 20 25 30Val Lys Thr Leu Lys Ala Gln Asn Ser Glu Leu Ala Ser Thr Ala Asn 35 40 45Met Leu Arg Glu Gln Val Ala Gln Leu Lys Gln Lys Val Met Gly Lys 50 55 60Ser Lys Arg Ser Lys Glu Pro Leu Arg Pro Arg Cys Arg Pro Ile Asn65 70 75 80Ala Thr Leu Ala Val Glu Lys Glu Gly Cys Pro Val Cys Ile Thr Val 85 90 95Asn Thr Thr Ile Cys Ala Gly Tyr Cys Pro Thr Met Thr Arg Val Leu 100 105 110Gln Gly Val Leu Pro Ala Leu Pro Gln Val Val Cys Asn Tyr Arg Asp 115 120 125Val Arg Phe Glu Ser Ile Arg Leu Pro Gly Cys Pro Arg Gly Val Asn 130 135 140Pro Val Val Ser Tyr Ala Val Ala Leu Ser Cys Gln Cys Ala Leu Cys145 150 155 160Asp Ser Asp Ser Thr Asp Cys Thr Val Arg Gly Leu Gly Pro Ser Tyr 165 170 175Cys Ser Phe Gly Glu Met Lys Glu Ser Ser Ser Ser Lys Ala Pro Pro 180 185 190Pro Ser Leu Pro Ser Pro Ser Arg Leu Pro Gly Pro Ser Asp Thr Pro 195 200 205Ile Leu Pro Gln 210 212 amino acids amino acid unknown unknown peptide NO NO 70Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Ser Cys Gly Gly Arg Ile Ala Arg Leu Glu Glu Lys 20 25 30Val Lys Thr Leu Lys Ala Gln Asn Ser Glu Leu Ala Ser Thr Ala Asn 35 40 45Met Leu Arg Glu Gln Val Ala Gln Leu Lys Gln Lys Val Met Gly Lys 50 55 60Ser Lys Arg Ser Lys Glu Pro Leu Arg Pro Arg Cys Arg Pro Ile Asn65 70 75 80Ala Thr Leu Ala Val Glu Lys Glu Gly Cys Pro Val Cys Ile Thr Val 85 90 95Asn Thr Thr Ile Cys Ala Gly Tyr Cys Pro Thr Met Thr Arg Val Leu 100 105 110Gln Gly Val Leu Pro Ala Leu Pro Gln Val Val Cys Asn Tyr Arg Asp 115 120 125Val Arg Phe Glu Ser Ile Arg Leu Pro Gly Cys Pro Arg Gly Val Asn 130 135 140Pro Val Val Ser Tyr Ala Val Ala Leu Ser Cys Gln Cys Ala Leu Cys145 150 155 160Asn Thr Asp Tyr Ser Asp Cys Ile His Glu Ala Ile Lys Thr Asn Tyr 165 170 175Cys Thr Lys Pro Gln Lys Ser Tyr Ser Ser Ser Ser Lys Ala Pro Pro 180 185 190Pro Ser Leu Pro Ser Pro Ser Arg Leu Pro Gly Pro Ser Asp Thr Pro 195 200 205Ile Leu Pro Gln 210 226 amino acids amino acid unknown unknown peptide NO NO 71Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Xaa Xaa Xaa Ala Asp Ala Ala Pro Thr Val Ser Ile 20 25 30Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala Ser Val Val 35 40 45Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys 50 55 60Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn Ser Trp Thr Asp65 70 75 80Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr Leu Thr Trp 85 90 95Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu Ala Thr 100 105 110His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg Asn Glu 115 120 125Cys Gly Lys Ser Lys Arg Ala Pro Asp Val Gln Asp Cys Pro Glu Cys 130 135 140Thr Leu Gln Glu Asn Pro Phe Phe Ser Gln Pro Gly Ala Pro Ile Leu145 150 155 160Gln Cys Met Gly Cys Cys Phe Ser Arg Ala Tyr Pro Thr Pro Leu Arg 165 170 175Ser Lys Lys Thr Met Leu Val Gln Lys Asn Val Thr Ser Glu Ser Thr 180 185 190Cys Cys Val Ala Lys Ser Tyr Asn Arg Val Thr Val Met Gly Gly Phe 195 200 205Lys Val Glu Asn His Thr Ala Cys His Cys Ser Thr Cys Tyr Tyr His 210 215 220Lys Ser225 276 amino acids amino acid unknown unknown peptide NO NO 72Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Xaa Xaa Xaa Ser Ala Lys Thr Thr Pro Pro Ser Val 20 25 30Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val Thr 35 40 45Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val Thr 50 55 60Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val65 70 75 80Leu Glu Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro Ser 85 90 95Ser Pro Arg Pro Ser Glu Thr Val Thr Cys Asn Val Ala His Pro Ala 100 105 110Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp Cys Gly Lys 115 120 125Ser Lys Arg Ser Lys Glu Pro Leu Arg Pro Arg Cys Arg Pro Ile Asn 130 135 140Ala Thr Leu Ala Val Glu Lys Glu Gly Cys Pro Val Cys Ile Thr Val145 150 155 160Asn Thr Thr Ile Cys Ala Gly Tyr Cys Pro Thr Met Thr Arg Val Leu 165 170 175Gln Gly Val Leu Pro Ala Leu Pro Gln Val Val Cys Asn Tyr Arg Asp 180 185 190Val Arg Phe Glu Ser Ile Arg Leu Pro Gly Cys Pro Arg Gly Val Asn 195 200 205Pro Val Val Ser Tyr Ala Val Ala Leu Ser Cys Gln Cys Ala Leu Cys 210 215 220Arg Arg Ser Thr Thr Asp Cys Gly Gly Pro Lys Asp His Pro Leu Thr225 230 235 240Cys Asp Asp Pro Arg Phe Gln Asp Ser Ser Ser Ser Lys Ala Pro Pro 245 250 255Pro Ser Leu Pro Ser Pro Ser Arg Leu Pro Gly Pro Ser Asp Thr Pro 260 265 270Ile Leu Pro Gln 275 245 amino acids amino acid unknown unknown peptide NO NO 73Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Xaa Xaa Xaa Ser Ala Lys Thr Thr Pro Pro Ser Val 20 25 30Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val Thr 35 40 45Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val Thr 50 55 60Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val65 70 75 80Leu Glu Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro Ser 85 90 95Ser Pro Arg Pro Ser Glu Thr Val Thr Cys Asn Val Ala His Pro Ala 100 105 110Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp Cys Gly Lys 115 120 125Ser Lys Arg Ser Arg Glu Pro Leu Arg Pro Trp Cys His Pro Ile Asn 130 135 140Ala Ile Leu Ala Val Glu Lys Glu Gly Cys Pro Val Cys Ile Thr Val145 150 155 160Asn Thr Thr Ile Cys Ala Gly Tyr Cys Pro Thr Met Met Arg Val Leu 165 170 175Gln Ala Val Leu Pro Pro Leu Pro Gln Val Val Cys Thr Tyr Arg Asp 180 185 190Val Arg Phe Glu Ser Ile Arg Leu Pro Gly Cys Pro Arg Gly Val Asp 195 200 205Pro Val Val Ser Phe Pro Val Ala Leu Ser Cys Arg Cys Ala Leu Cys 210 215 220Arg Arg Ser Thr Ser Asp Cys Gly Gly Pro Lys Asp His Pro Leu Thr225 230 235 240Cys Asp His Pro Gln 245 242 amino acids amino acid unknown unknown peptide NO NO 74Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Xaa Xaa Xaa Ser Ala Lys Thr Thr Pro Pro Ser Val 20 25 30Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val Thr 35 40 45Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val Thr 50 55 60Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val65 70 75 80Leu Glu Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro Ser 85 90 95Ser Pro Arg Pro Ser Glu Thr Val Thr Cys Asn Val Ala His Pro Ala 100 105 110Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp Cys Gly Lys 115 120 125Ser Lys Arg Asn Ser Cys Glu Leu Thr Asn Ile Thr Ile Ala Ile Glu 130 135 140Lys Glu Glu Cys Arg Phe Cys Ile Ser Ile Asn Thr Thr Trp Cys Ala145 150 155 160Gly Tyr Cys Tyr Thr Arg Asp Leu Val Tyr Lys Asp Pro Ala Arg Pro 165 170 175Lys Ile Gln Lys Thr Cys Thr Phe Lys Glu Leu Val Tyr Glu Thr Val 180 185 190Arg Val Pro Gly Cys Ala His His Ala Asp Ser Leu Tyr Thr Tyr Pro 195 200 205Val Ala Thr Gln Cys His Cys Gly Lys Cys Asp Ser Asp Ser Thr Asp 210 215 220Cys Thr Val Arg Gly Leu Gly Pro Ser Tyr Cys Ser Phe Gly Glu Met225 230 235 240Lys Glu 243 amino acids amino acid unknown unknown peptide NO NO 75Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Xaa Xaa Xaa Ser Ala Lys Thr Thr Pro Pro Ser Val 20 25 30Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val Thr 35 40 45Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val Thr 50 55 60Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val65 70 75 80Leu Glu Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro Ser 85 90 95Ser Pro Arg Pro Ser Glu Thr Val Thr Cys Asn Val Ala His Pro Ala 100 105 110Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp Cys Gly Lys 115 120 125Ser Lys Arg Phe Cys Ile Pro Thr Glu Tyr Thr Met His Ile Glu Arg 130 135 140Arg Glu Cys Ala Tyr Cys Leu Thr Ile Asn Thr Thr Ile Cys Ala Gly145 150 155 160Tyr Cys Met Thr Arg Asp Ile Asn Gly Lys Leu Phe Leu Pro Lys Tyr 165 170 175Ala Leu Ser Gln Asp Val Cys Thr Tyr Arg Asp Phe Ile Tyr Arg Thr 180 185 190Val Glu Ile Pro Gly Cys Pro Leu His Val Ala Pro Tyr Phe Ser Tyr 195 200 205Pro Val Ala Leu Ser Cys Lys Cys Gly Lys Cys Asn Thr Asp Tyr Ser 210 215 220Asp Cys Ile His Glu Ala Ile Lys Thr Asn Tyr Cys Thr Lys Pro Gln225 230 235 240Lys Ser Tyr 276 amino acids amino acid unknown unknown peptide NO NO 76Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Xaa Xaa Xaa Ser Ala Lys Thr Thr Pro Pro Ser Val 20 25 30Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val Thr 35 40 45Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val Thr 50 55 60Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val65 70 75 80Leu Glu Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro Ser 85 90 95Ser Pro Arg Pro Ser Glu Thr Val Thr Cys Asn Val Ala His Pro Ala 100 105 110Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp Cys Gly Lys 115 120 125Ser Lys Arg Ser Lys Glu Pro Leu Arg Pro Arg Cys Arg Pro Ile Asn 130 135 140Ala Thr Leu Ala Val Glu Lys Glu Gly Cys Pro Val Cys Ile Thr Val145 150 155 160Asn Thr Thr Ile Cys Ala Gly Tyr Cys Pro Thr Met Thr Arg Val Leu 165 170 175Gln Gly Val Leu Pro Ala Leu Pro Gln Val Val Cys Asn Tyr Arg Asp 180 185 190Val Arg Phe Glu Ser Ile Arg Leu Pro Gly Cys Pro Arg Gly Val Asn 195 200 205Pro Val Val Ser Tyr Ala Val Ala Leu Ser Cys Gln Cys Ala Leu Cys 210 215 220Asp Ser Asp Ser Thr Asp Cys Thr Val Arg Gly Leu Gly Pro Ser Tyr225 230 235 240Cys Ser Phe Gly Glu Met Lys Glu Ser Ser Ser Ser Lys Ala Pro Pro 245 250 255Pro Ser Leu Pro Ser Pro Ser Arg Leu Pro Gly Pro Ser Asp Thr Pro 260 265 270Ile Leu Pro Gln 275 276 amino acids amino acid unknown unknown peptide NO NO 77Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Xaa Xaa Xaa Ser Ala Lys Thr Thr Pro Pro Ser Val 20 25 30Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val Thr 35 40 45Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val Thr 50 55 60Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val65 70 75 80Leu Glu Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro Ser 85 90 95Ser Pro Arg Pro Ser Glu Thr Val Thr Cys Asn Val Ala His Pro Ala 100 105 110Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp Cys Gly Lys 115 120 125Ser Lys Arg Ser Lys Glu Pro Leu Arg Pro Arg Cys Arg Pro Ile Asn 130 135 140Ala Thr Leu Ala Val Glu Lys Glu Gly Cys Pro Val Cys Ile Thr Val145 150 155 160Asn Thr Thr Ile Cys Ala Gly Tyr Cys Pro Thr Met Thr Arg Val Leu 165 170 175Gln Gly Val Leu Pro Ala Leu Pro Gln Val Val Cys Asn Tyr Arg Asp 180 185 190Val Arg Phe Glu Ser Ile Arg Leu Pro Gly Cys Pro Arg Gly Val Asn 195 200 205Pro Val Val Ser Tyr Ala Val Ala Leu Ser Cys Gln Cys Ala Leu Cys 210 215 220Asn Thr Asp Tyr Ser Asp Cys Ile His Glu Ala Ile Lys Thr Asn Tyr225 230 235 240Cys Thr Lys Pro Gln Lys Ser Tyr Ser Ser Ser Ser Lys Ala Pro Pro 245 250 255Pro Ser Leu Pro Ser Pro Ser Arg Leu Pro Gly Pro Ser Asp Thr Pro 260 265 270Ile Leu Pro Gln 275 226 amino acids amino acid unknown unknown peptide NO NO 78Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Xaa Xaa Xaa Ala Asp Ala Ala Pro Thr Val Ser Ile 20 25 30Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala Ser Val Val 35 40 45Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys 50 55 60Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn Ser Trp Thr Asp65 70 75 80Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr Leu Thr Trp 85 90 95Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu Ala Thr 100 105 110His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg Asn Glu 115 120 125Ala Gly Lys Ser Lys Arg Ala Pro Asp Val Gln Asp Cys Pro Glu Cys 130 135 140Thr Leu Gln Glu Asn Pro Phe Phe Ser Gln Pro Gly Ala Pro Ile Leu145 150 155 160Gln Cys Met Gly Cys Cys Phe Ser Arg Ala Tyr Pro Thr Pro Leu Arg 165 170 175Ser Lys Lys Thr Met Leu Val Gln Lys Asn Val Thr Ser Glu Ser Thr 180 185 190Cys Cys Val Ala Lys Ser Tyr Asn Arg Val Thr Val Met Gly Gly Phe 195 200 205Lys Val Glu Asn His Thr Ala Cys His Cys Ser Thr Cys Tyr Tyr His 210 215 220Lys Ser225 276 amino acids amino acid unknown unknown peptide NO NO 79Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Xaa Xaa Xaa Ser Ala Lys Thr Thr Pro Pro Ser Val 20 25 30Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val Thr 35 40 45Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val Thr 50 55 60Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val65 70 75 80Leu Glu Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro Ser 85 90 95Ser Pro Arg Pro Ser Glu Thr Val Thr Cys Asn Val Ala His Pro Ala 100 105 110Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp Ala Gly Lys 115 120 125Ser Lys Arg Ser Lys Glu Pro Leu Arg Pro Arg Cys Arg Pro Ile Asn 130 135 140Ala Thr Leu Ala Val Glu Lys Glu Gly Cys Pro Val Cys Ile Thr Val145 150 155 160Asn Thr Thr Ile Cys Ala Gly Tyr Cys Pro Thr Met Thr Arg Val Leu 165 170 175Gln Gly Val Leu Pro Ala Leu Pro Gln Val Val Cys Asn Tyr Arg Asp 180 185 190Val Arg Phe Glu Ser Ile Arg Leu Pro Gly Cys Pro Arg Gly Val Asn 195 200 205Pro Val Val Ser Tyr Ala Val Ala Leu Ser Cys Gln Cys Ala Leu Cys 210 215 220Arg Arg Ser Thr Thr Asp Cys Gly Gly Pro Lys Asp His Pro Leu Thr225 230 235 240Cys Asp Asp Pro Arg Phe Gln Asp Ser Ser Ser Ser Lys Ala Pro Pro 245 250 255Pro Ser Leu Pro Ser Pro Ser Arg Leu Pro Gly Pro Ser Asp Thr Pro 260 265 270Ile Leu Pro Gln 275 245 amino acids amino acid unknown unknown peptide NO NO 80Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Xaa Xaa Xaa Ser Ala Lys Thr Thr Pro Pro Ser Val 20 25 30Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val Thr 35 40 45Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val Thr 50 55 60Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val65 70 75 80Leu Glu Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro Ser 85 90 95Ser Pro Arg Pro Ser Glu Thr Val Thr Cys Asn Val Ala His Pro Ala 100 105 110Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp Ala Gly Lys 115 120 125Ser Lys Arg Ser Arg Glu Pro Leu Arg Pro Trp Cys His Pro Ile Asn 130 135 140Ala Ile Leu Ala Val Glu Lys Glu Gly Cys Pro Val Cys Ile Thr Val145 150 155 160Asn Thr Thr Ile Cys Ala Gly Tyr Cys Pro Thr Met Met Arg Val Leu 165 170 175Gln Ala Val Leu Pro Pro Leu Pro Gln Val Val Cys Thr Tyr Arg Asp 180 185 190Val Arg Phe Glu Ser Ile Arg Leu Pro Gly Cys Pro Arg Gly Val Asp 195 200 205Pro Val Val Ser Phe Pro Val Ala Leu Ser Cys Arg Cys Ala Leu Cys 210 215 220Arg Arg Ser Thr Ser Asp Cys Gly Gly Pro Lys Asp His Pro Leu Thr225 230 235 240Cys Asp His Pro Gln 245 242 amino acids amino acid unknown unknown peptide NO NO 81Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Xaa Xaa Xaa Ser Ala Lys Thr Thr Pro Pro Ser Val 20 25 30Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val Thr 35 40 45Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val Thr 50 55 60Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val65 70 75 80Leu Glu Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro Ser 85 90 95Ser Pro Arg Pro Ser Glu Thr Val Thr Cys Asn Val Ala His Pro Ala 100 105 110Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp Ala Gly Lys 115 120 125Ser Lys Arg Asn Ser Cys Glu Leu Thr Asn Ile Thr Ile Ala Ile Glu 130 135 140Lys Glu Glu Cys Arg Phe Cys Ile Ser Ile Asn Thr Thr Trp Cys Ala145 150 155 160Gly Tyr Cys Tyr Thr Arg Asp Leu Val Tyr Lys Asp Pro Ala Arg Pro 165 170 175Lys Ile Gln Lys Thr Cys Thr Phe Lys Glu Leu Val Tyr Glu Thr Val 180 185 190Arg Val Pro Gly Cys Ala His His Ala Asp Ser Leu Tyr Thr Tyr Pro 195 200 205Val Ala Thr Gln Cys His Cys Gly Lys Cys Asp Ser Asp Ser Thr Asp 210 215 220Cys Thr Val Arg Gly Leu Gly Pro Ser Tyr Cys Ser Phe Gly Glu Met225 230 235 240Lys Glu 243 amino acids amino acid unknown unknown peptide NO NO 82Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Xaa Xaa Xaa Ser Ala Lys Thr Thr Pro Pro Ser Val 20 25 30Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val Thr 35 40 45Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val Thr 50 55 60Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val65 70 75 80Leu Glu Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro Ser 85 90 95Ser Pro Arg Pro Ser Glu Thr Val Thr Cys Asn Val Ala His Pro Ala 100 105 110Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp Ala Gly Lys 115 120 125Ser Lys Arg Phe Cys Ile Pro Thr Glu Tyr Thr Met His Ile Glu Arg 130 135 140Arg Glu Cys Ala Tyr Cys Leu Thr Ile Asn Thr Thr Ile Cys Ala Gly145 150 155 160Tyr Cys Met Thr Arg Asp Ile Asn Gly Lys Leu Phe Leu Pro Lys Tyr 165 170 175Ala Leu Ser Gln Asp Val Cys Thr Tyr Arg Asp Phe Ile Tyr Arg Thr 180 185 190Val Glu Ile Pro Gly Cys Pro Leu His Val Ala Pro Tyr Phe Ser Tyr 195 200 205Pro Val Ala Leu Ser Cys Lys Cys Gly Lys Cys Asn Thr Asp Tyr Ser 210 215 220Asp Cys Ile His Glu Ala Ile Lys Thr Asn Tyr Cys Thr Lys Pro Gln225 230 235 240Lys Ser Tyr 276 amino acids amino acid unknown unknown peptide NO NO 83Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Xaa Xaa Xaa Ser Ala Lys Thr Thr Pro Pro Ser Val 20 25 30Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val Thr 35 40 45Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val Thr 50 55 60Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val65 70 75 80Leu Glu Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro Ser 85 90 95Ser Pro Arg Pro Ser Glu Thr Val Thr Cys Asn Val Ala His Pro Ala 100 105 110Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp Ala Gly Lys 115 120 125Ser Lys Arg Ser Lys Glu Pro Leu Arg Pro Arg Cys Arg Pro Ile Asn 130 135 140Ala Thr Leu Ala Val Glu Lys Glu Gly Cys Pro Val Cys Ile Thr Val145 150 155 160Asn Thr Thr Ile Cys Ala Gly Tyr Cys Pro Thr Met Thr Arg Val Leu 165 170 175Gln Gly Val Leu Pro Ala Leu Pro Gln Val Val Cys Asn Tyr Arg Asp 180 185 190Val Arg Phe Glu Ser Ile Arg Leu Pro Gly Cys Pro Arg Gly Val Asn 195 200 205Pro Val Val Ser Tyr Ala Val Ala Leu Ser Cys Gln Cys Ala Leu Cys 210 215 220Asp Ser Asp Ser Thr Asp Cys Thr Val Arg Gly Leu Gly Pro Ser Tyr225 230 235 240Cys Ser Phe Gly Glu Met Lys Glu Ser Ser Ser Ser Lys Ala Pro Pro 245 250 255Pro Ser Leu Pro Ser Pro Ser Arg Leu Pro Gly Pro Ser Asp Thr Pro 260 265 270Ile Leu Pro Gln 275 276 amino acids amino acid unknown unknown peptide NO NO 84Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Xaa Xaa Xaa Ser Ala Lys Thr Thr Pro Pro Ser Val 20 25 30Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val Thr 35 40 45Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val Thr 50 55 60Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val65 70 75 80Leu Glu Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro Ser 85 90 95Ser Pro Arg Pro Ser Glu Thr Val Thr Cys Asn Val Ala His Pro Ala 100 105 110Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp Ala Gly Lys 115 120 125Ser Lys Arg Ser Lys Glu Pro Leu Arg Pro Arg Cys Arg Pro Ile Asn 130 135 140Ala Thr Leu Ala Val Glu Lys Glu Gly Cys Pro Val Cys Ile Thr Val145 150 155 160Asn Thr Thr Ile Cys Ala Gly Tyr Cys Pro Thr Met Thr Arg Val Leu 165 170 175Gln Gly Val Leu Pro Ala Leu Pro Gln Val Val Cys Asn Tyr Arg Asp 180 185 190Val Arg Phe Glu Ser Ile Arg Leu Pro Gly Cys Pro Arg Gly Val Asn 195 200 205Pro Val Val Ser Tyr Ala Val Ala Leu Ser Cys Gln Cys Ala Leu Cys 210 215 220Asn Thr Asp Tyr Ser Asp Cys Ile His Glu Ala Ile Lys Thr Asn Tyr225 230 235 240Cys Thr Lys Pro Gln Lys Ser Tyr Ser Ser Ser Ser Lys Ala Pro Pro 245 250 255Pro Ser Leu Pro Ser Pro Ser Arg Leu Pro Gly Pro Ser Asp Thr Pro 260 265 270Ile Leu Pro Gln 275 203 amino acids amino acid unknown unknown peptide NO NO 85Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Ser Lys Glu Pro Leu Arg Pro Arg Cys Arg Pro Ile 20 25 30Asn Ala Thr Leu Ala Val Glu Lys Glu Gly Cys Pro Val Cys Ile Thr 35 40 45Val Asn Thr Thr Ile Cys Ala Gly Tyr Cys Pro Thr Met Thr Arg Val 50 55 60Leu Gln Gly Val Leu Pro Ala Leu Pro Gln Val Val Cys Asn Tyr Arg65 70 75 80Asp Val Arg Phe Glu Ser Ile Arg Leu Pro Gly Cys Pro Arg Gly Val 85 90 95Asn Pro Val Val Ser Tyr Ala Val Ala Leu Ser Cys Gln Cys Ala Leu 100 105 110Cys Arg Arg Ser Thr Thr Asp Cys Gly Gly Pro Lys Asp His Pro Leu 115 120 125Thr Cys Asp Asp Pro Arg Phe Gln Asp Ser Ser Ser Ser Lys Ala Pro 130 135 140Pro Pro Ser Leu Pro Ser Pro Ser Arg Leu Pro Gly Pro Ser Asp Thr145 150 155 160Pro Ile Leu Pro Gln Arg Ile Ala Arg Leu Glu Glu Lys Val Lys Thr 165 170 175Leu Lys Ala Gln Asn Ser Glu Leu Ala Ser Thr Ala Asn Met Leu Arg 180 185 190Glu Gln Val Ala Gln Leu Lys Gln Lys Val Met 195 200 209 amino acids amino acid unknown unknown peptide NO NO 86Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Ser Lys Glu Pro Leu Arg Pro Arg Cys Arg Pro Ile 20 25 30Asn Ala Thr Leu Ala Val Glu Lys Glu Gly Cys Pro Val Cys Ile Thr 35 40 45Val Asn Thr Thr Ile Cys Ala Gly Tyr Cys Pro Thr Met Thr Arg Val 50 55 60Leu Gln Gly Val Leu Pro Ala Leu Pro Gln Val Val Cys Asn Tyr Arg65 70 75 80Asp Val Arg Phe Glu Ser Ile Arg Leu Pro Gly Cys Pro Arg Gly Val 85 90 95Asn Pro Val Val Ser Tyr Ala Val Ala Leu Ser Cys Gln Cys Ala Leu 100 105 110Cys Arg Arg Ser Thr Thr Asp Cys Gly Gly Pro Lys Asp His Pro Leu 115 120 125Thr Cys Asp Asp Pro Arg Phe Gln Asp Ser Ser Ser Ser Lys Ala Pro 130 135 140Pro Pro Ser Leu Pro Ser Pro Ser Arg Leu Pro Gly Pro Ser Asp Thr145 150 155 160Pro Ile Leu Pro Gln Gly Ser Gly Ser Gly Ser Arg Ile Ala Arg Leu 165 170 175Glu Glu Lys Val Lys Thr Leu Lys Ala Gln Asn Ser Glu Leu Ala Ser 180 185 190Thr Ala Asn Met Leu Arg Glu Gln Val Ala Gln Leu Lys Gln Lys Val 195 200 205Met 209 amino acids amino acid unknown unknown peptide NO NO 87Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Ser Arg Glu Pro Leu Arg Pro Trp Cys His Pro Ile 20 25 30Asn Ala Ile Leu Ala Val Glu Lys Glu Gly Cys Pro Val Cys Ile Thr 35 40 45Val Asn Thr Thr Ile Cys Ala Gly Tyr Cys Pro Thr Met Met Arg Val 50 55 60Leu Gln Ala Val Leu Pro Pro Leu Pro Gln Val Val Cys Thr Tyr Arg65 70 75 80Asp Val Arg Phe Glu Ser Ile Arg Leu Pro Gly Cys Pro Arg Gly Val 85 90 95Asp Pro Val Val Ser Phe Pro Val Ala Leu Ser Cys Arg Cys Ala Leu 100 105 110Cys Arg Arg Ser Thr Ser Asp Cys Gly Gly Pro Lys Asp His Pro Leu 115 120 125Thr Cys Asp Asp Pro Arg Phe Gln Asp Ser Ser Ser Ser Lys Ala Pro 130 135 140Pro Pro Ser Leu Pro Ser Pro Ser Arg Leu Pro Gly Pro Ser Asp Thr145 150 155 160Pro Ile Leu Pro Gln Gly Ser Gly Ser Gly Ser Arg Ile Ala Arg Leu 165 170 175Glu Glu Lys Val Lys Thr Leu Lys Ala Gln Asn Ser Glu Leu Ala Ser 180 185 190Thr Ala Asn Met Leu Arg Glu Gln Val Ala Gln Leu Lys Gln Lys Val 195 200 205Met 203 amino acids amino acid unknown unknown peptide NO NO 88Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Asn Ser Cys Glu Leu Thr Asn Ile Thr Ile Ala Ile 20 25 30Glu Lys Glu Glu Cys Arg Phe Cys Ile Ser Ile Asn Thr Thr Trp Cys 35 40 45Ala Gly Tyr Cys Tyr Thr Arg Asp Leu Val Tyr Lys Asp Pro Ala Arg 50 55 60Pro Lys Ile Gln Lys Thr Cys Thr Phe Lys Glu Leu Val Tyr Glu Thr65 70 75 80Val Arg Val Pro Gly Cys Ala His His Ala Asp Ser Leu Tyr Thr Tyr 85 90 95Pro Val Ala Thr Gln Cys His Cys Gly Lys Cys Asp Ser Asp Ser Thr 100 105 110Asp Cys Thr Val Arg Gly Leu Gly Pro Ser Tyr Cys Ser Phe Gly Glu 115 120 125Met Lys Glu Ser Ser Ser Ser Lys Ala Pro Pro Pro Ser Leu Pro Ser 130 135 140Pro Ser Arg Leu Pro Gly Pro Ser Asp Thr Pro Ile Leu Pro Gln Gly145 150 155 160Ser Gly Ser Gly Ser Arg Ile Ala Arg Leu Glu Glu Lys Val Lys Thr 165 170 175Leu Lys Ala Gln Asn Ser Glu Leu Ala Ser Thr Ala Asn Met Leu Arg 180 185 190Glu Gln Val Ala Gln Leu Lys Gln Lys Val Met 195 200 204 amino acids amino acid unknown unknown peptide NO NO 89Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Phe Cys Ile Pro Thr Glu Tyr Thr Met His Ile Glu 20 25 30Arg Arg Glu Cys Ala Tyr Cys Leu Thr Ile Asn Thr Thr Ile Cys Ala 35 40 45Gly Tyr Cys Met Thr Arg Asp Ile Asn Gly Lys Leu Phe Leu Pro Lys 50 55 60Tyr Ala Leu Ser Gln Asp Val Cys Thr Tyr Arg Asp Phe Ile Tyr Arg65 70 75 80Thr Val Glu Ile Pro Gly Cys Pro Leu His Val Ala Pro Tyr Phe Ser 85 90 95Tyr Pro Val Ala Leu Ser Cys Lys Cys Gly Lys Cys Asn Thr Asp Tyr 100 105 110Ser Asp Cys Ile His Glu Ala Ile Lys Thr Asn Tyr Cys Thr Lys Pro 115 120 125Gln Lys Ser Tyr Ser Ser Ser Ser Lys Ala Pro Pro Pro Ser Leu Pro 130 135 140Ser Pro Ser Arg Leu Pro Gly Pro Ser Asp Thr Pro Ile Leu Pro Gln145 150 155 160Gly Ser Gly Ser Gly Ser Arg Ile Ala Arg Leu Glu Glu Lys Val Lys 165 170 175Thr Leu Lys Ala Gln Asn Ser Glu Leu Ala Ser Thr Ala Asn Met Leu 180 185 190Arg Glu Gln Val Ala Gln Leu Lys Gln Lys Val Met 195 200 206 amino acids amino acid unknown unknown peptide NO NO 90Met Glu Met Phe Gln Gly Leu Leu Leu Leu Leu Leu Leu Ser Met Gly1 5 10 15Gly Thr Trp Ala Ser Lys Glu Pro Leu Arg Pro Arg Cys Arg Pro Ile 20 25 30Asn Ala Thr Leu Ala Val Glu Lys Glu Gly Cys Pro Val Cys Ile Thr 35 40 45Val Asn Thr Thr Ile Cys Ala Gly Tyr Cys Pro Thr Met Thr Arg Val 50 55 60Leu Gln Gly Val Leu Pro Ala Leu Pro Gln Val Val Cys Asn Tyr Arg65 70 75 80Asp Val Arg Phe Glu Ser Ile Arg Leu Pro Gly Cys Pro Arg Gly Val 85 90 95Asn Pro Val Val Ser Tyr Ala Val Ala Leu Ser Cys Gln Cys Ala Leu 100 105 110Cys Arg Arg Ser Thr Thr Asp Cys Gly Gly Pro Lys Asp His Pro Leu 115 120 125Thr Cys Asp Asp Pro Arg Phe Gln Asp Ser Ser Ser Ser Lys Ala Pro 130 135 140Pro Pro Ser Leu Pro Ser Pro Ser Arg Leu Pro Gly Pro Ser Asp Thr145 150 155 160Pro Ile Leu Pro Gln Cys Gly Gly Arg Ile Ala Arg Leu Glu Glu Lys 165 170 175Val Lys Thr Leu Lys Ala Gln Asn Ser Glu Leu Ala Ser Thr Ala Asn 180 185 190Met Leu Arg Glu Gln Val Ala Gln Leu Lys Gln Lys Val Met 195 200 205

Claims

1. A method for forming a subunit combination of a cysteine knot glycoprotein hormone having an α-subunit and a β-subunit to prepare a heterodimeric protein analog which comprises the steps of:(a) attaching a dimerization domain to the amino termini of both an α-subunit and a β-subunit of a cysteine knot glycoprotein hormone; and (b) dimerizing the α-subunit and β-subunit to form a heterodimeric protein analog.

2. The method according to claim 1, wherein a Fos dimerization sequence domain is attached to the amino-terminus of the β-subunit and a Jun dimerization sequence domain is attached to the amino-terminus of the α-subunit.

3. The method according to claim 1, wherein a Fos dimerization sequence domain is attached to the amino-terminus of the α-subunit and a Jun dimerization sequence domain is attached to the amino-terminus of the β-subunit.

4. The method according to claim 2, wherein a glycine or serine residue is inserted between the Fos or Jun dimerization sequence domain and a furin cleavage site to facilitate cleavage of the dimerization sequence domain from the heterodimer.

5. The method according to claim 3, wherein a glycine or serine residue is inserted between the Fos or Jun dimerization sequence domain and a furin cleavage site to facilitate cleavage of the dimerization sequence domain from the heterodimer.

6. The method according to claim 1, wherein the heterodimeric protein analog is selected from the group consisting of hCG/hFSH chimeras, hCG/hTSH chimeras, deglycosylated hormones, truncated glycoprotein hormones, mutant glycoprotein hormones, and glycoprotein hormones containing an hCG carboxyl terminus.

7. The method according to claim 1, further comprising incorporating protease cleavage sites between additional N-terminal sequences and the α-subunit and the β-subunit of the cysteine knot protein to remove the dimerization domains from the heterodimeric protein analog.

8. The method according to claim 1, wherein the cysteine knot glycoprotein hormone has an oligosaccharide genetically removed from the α-subunit at Asn52.

9. The method according to claim 1, wherein the cysteine knot glycoprotein hormone lacks a seatbelt.

10. A method for forming a subunit combination of a cysteine knot glycoprotein hormone having an α-subunit and a β-subunit to prepare a heterodimeric protein analog which comprises the steps of:(a) attaching a dimerization domain to the amino terminus of an α-subunit and the carboxy terminus of a β-subunit of a cysteine knot glycoprotein hormone; and (b) dimerizing the α-subunit and β-subunit to form a heterodimeric protein analog.

11. The method according to claim 10, wherein a Fos dimerization sequence domain is attached to the carboxy-terminus of the β-subunit and a Jun dimerization sequence domain is attached to the amino-terminus of the α-subunit.

12. The method according to claim 10, wherein a Fos dimerization sequence domain is attached to the amino-terminus of the α-subunit and a Jun dimerization sequence domain is attached to the carboxy terminus of the β-subunit.

13. The method according to claim 11, wherein a protease cleavage site is inserted between the dimerization sequence domain and the α-subunit and a protease cleavage site is inserted between the dimerization sequence domain and the β-subunit.

14. The method according to claim 13, wherein the protease cleavage site is furin.

15. The method according to claim 10, wherein the heterodimeric protein analog is selected from the group consisting of hCG/hFSH chimeras, hCG/hTSH chimeras, deglycosylated hormones, truncated glycoprotein hormones, mutant glycoprotein hormones, and glycoprotein hormones containing an hCG carboxyl terminus.

16. The method according to claim 10, wherein the cysteine knot glycoprotein hormone has an oligosaccharide genetically removed from the α-subunit at Asn52.

17. The method according to claim 1, wherein a Fos dimerization sequence domain is attached to the amino-terminus of an hCG β-subunit and a Jun dimerization sequence domain is attached to the amino-terminus of an hFSH α-subunit.

18. The method according to claim 10, wherein a Fos dimerization sequence domain is attached to the carboxy-terminus of an hCG β-subunit and a Jun dimerization sequence domain is attached to the amino-terminus of an hFSH α-subunit.